Kaj Blennow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3300767/publications.pdf

Version: 2024-02-01

199 314 1,399 119,220 155 297 citations h-index g-index papers 62759 1519 1519 1519 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
2	Testâ€retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.4	24
3	Genotypic effects of <i>APOE</i> -ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. Cerebral Cortex, 2023, 33, 2748-2760.	1.6	5
4	Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers. Translational Stroke Research, 2022, 13, 65-76.	2.3	17
5	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. Alzheimer's and Dementia, 2022, 18, 65-76.	0.4	18
6	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.4	5
7	Biomarkers of Cerebral Injury for Prediction of Postoperative Cognitive Dysfunction in Patients Undergoing Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 125-132.	0.6	17
8	Stateâ€ofâ€theâ€art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.4	33
9	Dynamics of Selected Biomarkers in Cerebrospinal Fluid During Complex Endovascular Aortic Repair – A Pilot Study. Annals of Vascular Surgery, 2022, 78, 141-151.	0.4	1
10	Cardiac troponin T is elevated and increases longitudinally in ALS patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 58-65.	1.1	8
11	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and pâ€ŧau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
12	Cohort Analysis of the Association of Delirium Severity With Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 494-501.	1.7	20
13	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 788-801.	2.4	8
14	Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study. Multiple Sclerosis Journal, 2022, 28, 872-884.	1.4	10
15	Response to mitogenâ€activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. British Journal of Haematology, 2022, 196, 248-254.	1.2	9
16	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 875-887.	0.4	22
17	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. Aids, 2022, 36, 75-82.	1.0	7
18	Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1141-1154.	0.4	89

#	Article	IF	Citations
19	Comparing the effect of xenon and sevoflurane anesthesia on postoperative neural injury biomarkers: a randomized controlled trial. Medical Gas Research, 2022, 12, 10.	1.2	8
20	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70-year-olds. European Journal of Nutrition, 2022, 61, 871-884.	1.8	15
21	Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. Journal of Affective Disorders, 2022, 297, 623-633.	2.0	13
22	Axonal Injury Partially Mediates Associations Between Increased Left Ventricular Mass Index and White Matter Damage. Stroke, 2022, 53, 808-816.	1.0	0
23	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
24	The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow coma scale score and days in intensive care. Journal of Neuroradiology, 2022, 49, 421-427.	0.6	13
25	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	4.5	38
26	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203
27	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	1.4	44
28	Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. Journal of Neurology, 2022, 269, 3064-3074.	1.8	8
29	Characterization of preâ€analytical sample handling effects on a panel of Alzheimer's disease–related bloodâ€based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.4	84
30	GFAp and tau protein as predictors of neurological outcome after out-of-hospital cardiac arrest: A post hoc analysis of the COMACARE trial. Resuscitation, 2022, 170, 141-149.	1.3	13
31	Plasma pâ€ŧau ₁₈₁ shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's and Dementia, 2022, 18, 1523-1536.	0.4	18
32	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	2.7	4
33	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2834-2848.	3.7	20
34	Plasma pâ€ŧau231, pâ€ŧau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	2.8	42
35	Functional brain activity constrained by structural connectivity reveals cohort-specific features for serum neurofilament light chain. Communications Medicine, 2022, 2, .	1.9	2
36	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	1.4	8

#	Article	IF	CITATIONS
37	Is amyloid involved in acute neuroinflammation? A CSF analysis in encephalitis. Alzheimer's and Dementia, 2022, , .	0.4	3
38	Association of APOE É⁄4 and Plasma p-tau181 with Preclinical Alzheimer's Disease and Longitudinal Change in Hippocampus Function. Journal of Alzheimer's Disease, 2022, 85, 1309-1320.	1.2	11
39	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.4	24
40	Crosswalk study on blood collectionâ€tube types for Alzheimer's disease biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12266.	1.2	8
41	Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. Fluids and Barriers of the CNS, 2022, 19, 11.	2.4	18
42	Amyloid processing in <scp>COVID</scp> â€19â€associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	2.1	35
43	Serum biomarkers of brain injury after uncomplicated cardiac surgery: Secondary analysis from a randomized trial. Acta Anaesthesiologica Scandinavica, 2022, 66, 447-453.	0.7	14
44	Slowing gait speed precedes cognitive decline by several years. Alzheimer's and Dementia, 2022, 18, 1667-1676.	0.4	24
45	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics. Frontiers in Neurology, 2022, 13, 826423.	1.1	7
46	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	2.7	65
47	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	3.0	49
48	Postoperative delirium and changes in the blood–brain barrier, neuroinflammation, and cerebrospinal fluid lactate: a prospective cohort study. British Journal of Anaesthesia, 2022, 129, 219-230.	1.5	55
49	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	2.7	34
50	Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury. Emergency Medicine Journal, 2022, 39, 206-212.	0.4	7
51	Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12295.	1.2	11
52	Bloodâ€brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor proteinâ€Î² in patients with subcortical smallâ€vessel disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12296.	1.2	5
53	Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2022, 19, 15.	2.4	7
54	Cerebral Biomarkers and Blood-Brain Barrier Integrity in Preeclampsia. Cells, 2022, 11, 789.	1.8	6

#	Article	IF	CITATIONS
55	CSF biomarkers and plasma pâ€ŧau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design. Alzheimer's and Dementia, 2022, 18, 2614-2626.	0.4	22
56	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	1.4	7
57	Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. Journal of Alzheimer's Disease, 2022, 85, 1721-1734.	1.2	3
58	Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis. Alzheimer's and Dementia, 2022, , .	0.4	3
59	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	3.9	89
60	Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Communications, 2022, 4, fcac066.	1.5	10
61	Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study. Brain Communications, 2022, 4, fcac040.	1.5	8
62	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. Brain Injury, 2022, 36, 800-809.	0.6	7
63	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	4.9	210
64	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
65	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. Alzheimer's Research and Therapy, 2022, 14, 46.	3.0	17
66	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
67	Age, sex and APOE-l μ 4 modify the balance between soluble and fibrillar l 2 -amyloid in non-demented individuals: topographical patterns across two independent cohorts. Molecular Psychiatry, 2022, 27, 2010-2018.	4.1	9
68	Cerebral biomarkers in neurologic complications of preeclampsia. American Journal of Obstetrics and Gynecology, 2022, 227, 298.e1-298.e10.	0.7	7
69	Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease. Frontiers in Neurology, 2022, 13, 839307.	1.1	8
70	Development of Fluid Biomarkers for Alzheimer's Disease. , 2022, , 361-374.		0
71	Post-acute blood biomarkers and disease progression in traumatic brain injury. Brain, 2022, 145, 2064-2076.	3.7	37
72	Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease. Translational Psychiatry, 2022, 12, 151.	2.4	16

#	Article	IF	CITATIONS
73	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	4.9	72
74	Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnestic Subtypes of Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2022, 14, 755454.	1.7	2
75	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
76	Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging. Journal of Neurochemistry, 2022, 160, 482-498.	2.1	17
77	γâ€Secretase modulators show selectivity for γâ€secretase–mediated amyloid precursor protein intramembrane processing. Journal of Cellular and Molecular Medicine, 2022, 26, 880-892.	1.6	4
78	Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. Brain, 2022, 145, 2149-2160.	3.7	20
79	Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest. Neurology, 2022, 98, .	1.5	7
80	Effect of Race on Prediction of Brain Amyloidosis by Plasma Al̂^242/Al̂^240, Phosphorylated Tau, and Neurofilament Light. Neurology, 2022, 99, .	1.5	63
81	Statistical Parametric Mapping in Amyloid Positron Emission Tomography. Frontiers in Aging Neuroscience, 2022, 14, 849932.	1.7	4
82	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. Neurobiology of Aging, 2022, 116, 80-91.	1.5	5
83	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	5.3	73
84	Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis– a prospective follow-up study. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1124-1132.	1.4	3
85	Alzheimer's Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dementia and Geriatric Cognitive Disorders, 2022, 51, 182-192.	0.7	16
86	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. Brain, 2022, 145, 3546-3557.	3.7	15
87	Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, 9, 882-887.	1.7	5
88	Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 65.	3.0	25
89	Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders, 2022, 63, 103846.	0.9	3
90	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers. Clinical Proteomics, 2022, 19, 13.	1.1	10

#	Article	IF	Citations
91	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022, 18, 400-418.	4.9	99
92	Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. British Journal of Haematology, 2022, , .	1.2	7
93	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	3.0	12
94	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	1.1	9
95	Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. European Journal of Neurology, 2022, 29, 2810-2822.	1.7	20
96	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.5	8
97	Association of Plasma Biomarker Levels With Their CSF Concentration and the Number and Severity of Concussions in Professional Athletes. Neurology, 2022, 99, .	1.5	10
98	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	11
99	Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1859-1870.	1.4	14
100	Reply to "Pathway for ascertaining the role of uric acid in neurodegenerative diseases,―Roman Youssef. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	0
101	Investigating the use of plasma pTau181 in retired contact sports athletes. Journal of Neurology, 2022, 269, 5582-5595.	1.8	4
102	Inflammation, tau pathology, and synaptic integrity associated with sleep spindles and memory prior to \hat{l}^2 -amyloid positivity. Sleep, 2022, 45, .	0.6	22
103	Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	1.8	5
104	Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis. Journal of Central Nervous System Disease, 2022, 14, 117957352210981.	0.7	2
105	Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie. International Journal of Molecular Sciences, 2022, 23, 7182.	1.8	3
106	Establishment of reference values for plasma neurofilament light based on healthy individuals aged $5\hat{a}\in 90$ years. Brain Communications, 2022, 4, .	1.5	57
107	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4567-4579.	3.3	16
108	Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury. European Child and Adolescent Psychiatry, 2021, 30, 1907-1915.	2.8	11

#	Article	IF	CITATIONS
109	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	4.1	76
110	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. Journal of Neurochemistry, 2021, 159, 389-402.	2.1	20
111	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. Molecular Psychiatry, 2021, 26, 5940-5954.	4.1	56
112	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5989-6001.	4.1	28
113	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63
114	CSF α-synuclein correlates with CSF neurogranin in late-life depression. International Journal of Neuroscience, 2021, 131, 357-361.	0.8	10
115	Postanoxic electrographic status epilepticus and serum biomarkers of brain injury. Resuscitation, 2021, 158, 253-257.	1.3	14
116	Determining Amyloid- \hat{l}^2 Positivity Using $\langle sup \rangle 18 \langle sup \rangle F$ -AZD4694 PET Imaging. Journal of Nuclear Medicine, 2021, 62, 247-252.	2.8	65
117	Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. Sleep, 2021, 44, .	0.6	22
118	No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS) Tj ETQq0	O 0.9 gBT /	'Oværlock 10
119	Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. European Journal of Neurology, 2021, 28, 587-594.	1.7	6
120	Association between cerebrospinal fluid biomarkers of neuronal injury or amyloidosis and cognitive decline after major surgery. British Journal of Anaesthesia, 2021, 126, 467-476.	1.5	17
121	Molecular forms of neurogranin in cerebrospinal fluid. Journal of Neurochemistry, 2021, 157, 816-833.	2.1	6
122	Headâ€toâ€head comparison of clinical performance of CSF phosphoâ€tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 755-767.	0.4	81
123	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
124	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
125	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Brain, 2021, 144, 325-339.	3.7	124
126	Untangling the association of amyloid- \hat{l}^2 and tau with synaptic and axonal loss in Alzheimer $\hat{a} \in \mathbb{N}$ s disease. Brain, 2021, 144, 310-324.	3.7	123

#	Article	IF	CITATIONS
127	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, 822-830.	0.4	27
128	Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. British Journal of Anaesthesia, 2021, 126, 458-466.	1.5	75
129	Associations between mean arterial pressure during cardiopulmonary bypass and biomarkers of cerebral injury in patients undergoing cardiac surgery: secondary results from a randomized controlled trial. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 229-235.	0.5	11
130	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 729-741.	1.2	10
131	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimer's and Dementia, 2021, 17, 431-445.	0.4	80
132	Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury. Clinica Chimica Acta, 2021, 512, 74-83.	0.5	8
133	Plasma neurofilament light chain as a potential biomarker in Charcotâ€Marieâ€Tooth disease. European Journal of Neurology, 2021, 28, 974-981.	1.7	30
134	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathologica, 2021, 141, 217-233.	3.9	33
135	Proinflammatory protein signatures in cryptogenic and large artery atherosclerosis stroke. Acta Neurologica Scandinavica, 2021, 143, 303-312.	1.0	9
136	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	4.1	186
137	Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. Journal of Neurology, 2021, 268, 1385-1394.	1.8	18
138	36â€month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 29-40.	0.4	77
139	Serumâ€neuroproteins, nearâ€infrared spectroscopy, and cognitive outcome after beachâ€chair shoulder surgery: Observational cohort study analyses. Acta Anaesthesiologica Scandinavica, 2021, 65, 26-33.	0.7	5
140	Neurofilament light as an outcome predictor after cardiac arrest: a post hoc analysis of the COMACARE trial. Intensive Care Medicine, 2021, 47, 39-48.	3.9	90
141	Association of Early \hat{l}^2 -Amyloid Accumulation and Neuroinflammation Measured With [$<$ sup> $11sup> C]PBR28 in Elderly Individuals Without Dementia. Neurology, 2021, 96, e1608-e1619.$	1.5	30
142	A Non- <i>APOE</i> Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 983-990.	1.7	18
143	Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. Journal of Alzheimer's Disease, 2021, 79, 225-235.	1.2	4
144	Effects of preâ€analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12168.	1.2	52

#	Article	IF	CITATIONS
145	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12141.	1.2	9
146	Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging preâ€analytical conditions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12145.	1.2	17
147	The relationship between white matter microstructure and self-perceived cognitive decline. NeuroImage: Clinical, 2021, 32, 102794.	1.4	9
148	Measurement batch differences and betweenâ€batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12194.	1,2	2
149	Parkinson's disease with restless legs syndromeâ€"an in vivo corneal confocal microscopy study. Npj Parkinson's Disease, 2021, 7, 4.	2.5	10
150	Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. Journal of Neurosurgery: Spine, 2021, 34, 1-10.	0.9	7
151	Plasma metabolomics of presymptomatic <i>PSEN1</i> â€H163Y mutation carriers: a pilot study. Annals of Clinical and Translational Neurology, 2021, 8, 579-591.	1.7	0
152	A Westernâ€style dietary pattern is associated with cerebrospinal fluid biomarker levels for preclinical Alzheimer's diseaseâ€"A populationâ€based crossâ€sectional study among 70â€yearâ€olds. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12183.	1.8	11
153	Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVIDâ€19 and associated with neurological symptoms and disease severity. European Journal of Neurology, 2021, 28, 3324-3331.	1.7	109
154	Headâ€toâ€head comparison of amplified plasmonic exosome Aβ42 platform and singleâ€molecule array immunoassay in a memory clinic cohort. European Journal of Neurology, 2021, 28, 1479-1489.	1.7	11
155	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Research and Therapy, 2021, 13, 17.	3.0	35
156	Plasma $\hat{l}^2 \hat{a} \in \mathbf{s}$ ecretase 1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. Alzheimer's and Dementia, 2021, 17, 629-640.	0.4	10
157	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	2.4	17
158	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 2021, 16, 10.	4.4	101
159	Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	1.5	51
160	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. Alzheimer's Research and Therapy, 2021, 13, 38.	3.0	12
161	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in nonâ€demented individuals with autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 813-821.	0.4	8
162	Age-Related Tau Burden and Cognitive Deficits Are Attenuated in KLOTHO KL-VS Heterozygotes. Journal of Alzheimer's Disease, 2021, 79, 1297-1305.	1,2	14

#	Article	IF	Citations
163	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	3.9	285
164	Signs of neuroaxonal injury in preeclampsiaâ€"A case control study. PLoS ONE, 2021, 16, e0246786.	1.1	17
165	Predicting neurological outcome after out-of-hospital cardiac arrest with cumulative information; development and internal validation of an artificial neural network algorithm. Critical Care, 2021, 25, 83.	2.5	23
166	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 46.	3.0	9
167	Association of Depressive Symptoms With Postoperative Delirium and CSF Biomarkers for Alzheimer's Disease Among Hip Fracture Patients. American Journal of Geriatric Psychiatry, 2021, 29, 1212-1221.	0.6	16
168	Plasma Pâ€tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimer's and Dementia, 2021, 17, 1649-1662.	0.4	37
169	Cerebral amyloidâ€Î² load is associated with neurodegeneration and gliosis: Mediation by pâ€ŧau and interactions with risk factors early in the Alzheimer's <i>continuum</i> . Alzheimer's and Dementia, 2021, 17, 788-800.	0.4	14
170	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18
171	Proteomic blood profiling in mild, severe and critical COVID-19 patients. Scientific Reports, 2021, 11, 6357.	1.6	72
172	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2121-2139.	3.3	43
173	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \hat{l}^2 and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.4	51
174	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
175	Negligible influence of moderate to severe hyperthermia on blood-brain barrier permeability and neuronal parenchymal integrity in healthy men. Journal of Applied Physiology, 2021, 130, 792-800.	1.2	6
176	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
177	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	3.3	83
178	Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies. Lupus Science and Medicine, 2021, 8, e000463.	1.1	8
179	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. Journal of Neurology, 2021, 268, 3574-3583.	1.8	56
180	Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression. Alzheimer's Research and Therapy, 2021, 13, 65.	3.0	49

#	Article	IF	Citations
181	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	3.0	6
182	Acute hyperglycaemia leads to altered frontal lobe brain activity and reduced working memory in type 2 diabetes. PLoS ONE, 2021, 16, e0247753.	1.1	16
183	Association of CSF proteins with tau and amyloid \hat{l}^2 levels in asymptomatic 70-year-olds. Alzheimer's Research and Therapy, 2021, 13, 54.	3.0	9
184	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 69.	3.0	34
185	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	3.7	16
186	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. Journal of Neuroimmunology, 2021, 353, 577493.	1.1	4
187	No neurochemical evidence of neuronal injury or glial activation in children with Paediatric Acute-onset Neuropsychiatric Syndrome. An explorative pilot study. World Journal of Biological Psychiatry, 2021, 22, 800-804.	1.3	2
188	Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimer's Research and Therapy, 2021, 13, 86.	3.0	19
189	TREM2 expression in the brain and biological fluids in prion diseases. Acta Neuropathologica, 2021, 141, 841-859.	3.9	18
190	Synergistic Association between Plasma Aβ _{1–42} and p-tau in Alzheimer's Disease but Not in Parkinson's Disease or Frontotemporal Dementia. ACS Chemical Neuroscience, 2021, 12, 1376-1383.	1.7	9
191	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.4	44
192	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	1.5	15
193	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	4.5	146
194	Analysis of Brain Injury Biomarker Neurofilament Light and Neurodevelopmental Outcomes and Retinopathy of Prematurity Among Preterm Infants. JAMA Network Open, 2021, 4, e214138.	2.8	15
195	Postoperative troponin increases after noncardiac surgery are associated with raised neurofilament light: a prospective observational cohort study. British Journal of Anaesthesia, 2021, 126, 791-798.	1.5	15
196	One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury. Frontiers in Neurology, 2021, 12, 643743.	1.1	20
197	Plasma neurofilament light chain levels predict improvement in late phase after stroke. European Journal of Neurology, 2021, 28, 2218-2228.	1.7	10
198	Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population. Frontiers in Aging Neuroscience, 2021, 13, 659898.	1.7	9

#	Article	IF	CITATIONS
199	Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains. Neuroscience Letters, 2021, 754, 135894.	1.0	9
200	Effects of amyloid pathology and the APOE $\hat{l}\mu4$ allele on the association between cerebrospinal fluid A \hat{l}^238 and A \hat{l}^240 and brain morphology in cognitively normal 70-years-olds. Neurobiology of Aging, 2021, 101, 1-12.	1.5	7
201	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. Journal of Affective Disorders, 2021, 286, 275-281.	2.0	9
202	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE, 2021, 16, e0250987.	1,1	30
203	Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. Neurology, 2021, , 10.1212/WNL.00000000012145.	1.5	8
204	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
205	Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2021, 18, 23.	2.4	10
206	Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium. Journal of Alzheimer's Disease, 2021, 81, 667-677.	1.2	2
207	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23
208	Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy. PLoS ONE, 2021, 16, e0248980.	1.1	14
209	Complex Autoantibody Responses Occur following Moderate to Severe Traumatic Brain Injury. Journal of Immunology, 2021, 207, 90-100.	0.4	24
210	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
211	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	4.9	396
212	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	0.9	30
213	Following spatial Aβ aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. Science Advances, 2021, 7, .	4.7	22
214	Clinical Utility of \hat{I}^2 -Amyloid PET Imaging in People Living With HIV With Cognitive Symptoms. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 826-833.	0.9	5
215	Multiâ€cohort profiling reveals elevated CSF levels of brainâ€enriched proteins in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 1456-1470.	1.7	19
216	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. Aids, 2021, 35, 2129-2136.	1.0	6

#	Article	IF	Citations
217	Spitting image: can saliva biomarkers reflect Alzheimer's disease?. EBioMedicine, 2021, 68, 103437.	2.7	9
218	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	2.7	54
219	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
220	Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications, 2021, 3, fcab136.	1.5	33
221	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. Neurobiology of Aging, 2021, 102, 151-160.	1.5	6
222	<scp>CSF</scp> Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in <scp>PD</scp> and <scp>DLB</scp> . Movement Disorders, 2021, 36, 2595-2604.	2.2	15
223	Refining the amyloid β peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
224	Cognitively unimpaired individuals with a low burden of $\hat{Al^2}$ pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134.	3.0	8
225	Circulating granulocyte colony-stimulating factor and functional outcome after ischemic stroke: an observational study. Neurological Research, 2021, 43, 1013-1022.	0.6	0
226	Circulating brain injury biomarkers increase after endoscopic surgery for pituitary tumors. Journal of Clinical Neuroscience, 2021, 89, 113-121.	0.8	5
227	Tau PET correlates with different Alzheimer's diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
228	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. Menopause, 2021, 28, 1099-1107.	0.8	6
229	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	1.8	34
230	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.5	50
231	Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. Journal of Allergy and Clinical Immunology, 2021, 148, 96-98.	1.5	47
232	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	5.8	33
233	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain, 2021, 144, 3505-3516.	3.7	198
234	Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritisâ€"a spin-off study of the NORD-STAR randomized clinical trial. Arthritis Research and Therapy, 2021, 23, 189.	1.6	5

#	Article	IF	CITATIONS
235	Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews Neurology, 2021, 17, 580-589.	4.9	144
236	Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clinical Neurophysiology, 2021, 132, 1733-1740.	0.7	94
237	Amyloid- \hat{l}^2 positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging, 2021, 104, 24-31.	1.5	13
238	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
239	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine, 2021, 70, 103512.	2.7	106
240	Microglial activation and tau propagate jointly across Braak stages. Nature Medicine, 2021, 27, 1592-1599.	15.2	235
241	Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 355-366.	1.2	1
242	Association of Apolipoprotein E É>4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	4.5	32
243	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. Alzheimer's Research and Therapy, 2021, 13, 135.	3.0	30
244	Phenotyping Alzheimer's disease with blood tests. Science, 2021, 373, 626-628.	6.0	21
245	Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage. Scientific Reports, 2021, 11, 16950.	1.6	5
246	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3639.	1.0	17
247	The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	4.1	478
248	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Medicine, 2021, 47, 984-994.	3.9	50
249	Ultra-Early Differential Diagnosis of Acute Cerebral Ischemia and Hemorrhagic Stroke by Measuring the Prehospital Release Rate of GFAP. Clinical Chemistry, 2021, 67, 1361-1372.	1.5	21
250	Head-to-Head Comparison of 8 Plasma Amyloid- \hat{l}^2 42/40 Assays in Alzheimer Disease. JAMA Neurology, 2021, 78, 1375.	4.5	195
251	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. Clinical Chemistry and Laboratory Medicine, 2021, 60, e13-e17.	1.4	0
252	The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients. Alzheimer's Research and Therapy, 2021, 13, 161.	3.0	15

#	Article	IF	Citations
253	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
254	Effects of Peroral Omega-3 Fatty Acid Supplementation on Cerebrospinal Fluid Biomarkers in Patients with Alzheimer's Disease: A Randomized Controlled Trial—The OmegAD Study. Journal of Alzheimer's Disease, 2021, 83, 1291-1301.	1.2	10
255	Association of deranged cerebrovascular reactivity with brain injury following cardiac arrest: a post-hoc analysis of the COMACARE trial. Critical Care, 2021, 25, 350.	2.5	17
256	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2021, 84, 119-128.	1.2	3
257	Amyloid pathology and synaptic loss in pathological aging. Journal of Neurochemistry, 2021, 159, 258-272.	2.1	6
258	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nature Genetics, 2021, 53, 1276-1282.	9.4	430
259	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
260	Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A realâ€world investigation. Journal of Neurochemistry, 2021, 159, 618-628.	2.1	26
261	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. EClinicalMedicine, 2021, 39, 101070.	3.2	21
262	Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 151.	3.0	9
263	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1231-1241.	0.9	51
264	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. Journal of Affective Disorders, 2021, 293, 429-434.	2.0	5
265	A genome-wide association study of plasma phosphorylated tau181. Neurobiology of Aging, 2021, 106, 304.e1-304.e3.	1.5	5
266	Sulfatide in health and disease. The evaluation of sulfatide in cerebrospinal fluid as a possible biomarker for neurodegeneration. Molecular and Cellular Neurosciences, 2021, 116, 103670.	1.0	17
267	Association of plasma \hat{A}^240/\hat{A}^242 ratio and brain \hat{A}^2 accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69.	1.5	5
268	Brain injury markers in new-onset seizures in adults: A pilot study. Seizure: the Journal of the British Epilepsy Association, 2021, 92, 62-67.	0.9	11
269	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Environment International, 2021, 157, 106864.	4.8	40
270	Tau aggregation and increased neuroinflammation in athletes after sports-related concussions and in traumatic brain injury patients – A PET/MR study. NeuroImage: Clinical, 2021, 30, 102665.	1.4	29

#	Article	IF	Citations
271	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
272	Polygenic risk scores for Alzheimer's disease are related to dementia risk in APOE É>4 negatives. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12142.	1.2	25
273	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Translational Psychiatry, 2021, 11, 27.	2.4	207
274	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	2.9	131
275	Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes. Brain Communications, 2021, 3, fcab099.	1.5	43
276	Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification. Alzheimer's and Dementia, 2021, 17, 1365-1382.	0.4	43
277	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54
278	The global Alzheimer's Association round robin study on plasma amyloid \hat{l}^2 methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242.	1.2	17
279	Serum Neurofilament Light is elevated in COVID-19 Positive Adults in the ICU and is associated with Co-Morbid Cardiovascular Disease, Neurological Complications, and Acuity of Illness. Cardiology and Cardiovascular Medicine, 2021, 05, 551-565.	0.1	8
280	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€"part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	3.0	35
281	Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight. JAMA Neurology, 2021, 78, 1525.	4.5	19
282	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. Scientific Reports, 2021, 11, 20375.	1.6	9
283	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 573-584.	0.7	3
284	Lower plasma total tau in adolescent psychosis: Involvement of the orbitofrontal cortex. Journal of Psychiatric Research, 2021, 144, 255-261.	1.5	3
285	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 175.	2.4	49
286	Pâ€ŧau235: a novel biomarker for staging preclinical Alzheimer's disease. EMBO Molecular Medicine, 2021, 13, e15098.	3.3	30
287	Differences Between Plasma and Cerebrospinal Fluid Clial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	4.5	204
288	Evidence of Neuroinflammation and Blood–Brain Barrier Disruption in Women with Preeclampsia and Eclampsia. Cells, 2021, 10, 3045.	1.8	11

#	Article	IF	Citations
289	Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Communications Biology, 2021, 4, 1265.	2.0	4
290	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7
291	Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188.	3.0	8
292	Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Scientific Reports, 2021, 11, 22128.	1.6	31
293	Association between serum urate and CSF markers of Alzheimer's disease pathology in a populationâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12241.	1.2	3
294	The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans. Frontiers in Physiology, 2021, 12, 769948.	1.3	15
295	Cerebrospinal Fluid Biomarkers, Brain Structural and Cognitive Performances Between Normotensive and Hypertensive Controlled, Uncontrolled and Untreated 70-Year-Old Adults. Frontiers in Aging Neuroscience, 2021, 13, 777475.	1.7	4
296	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, $2021,17,.$	0.4	6
297	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	3.0	87
298	Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer's continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	1
299	Neurochemical signs of astrocytic and neuronal injury in acute COVIDâ€19 normalizes during longâ€term followâ€up. Alzheimer's and Dementia, 2021, 17, .	0.4	2
300	Associations between obstructive sleep apnea, Alzheimer's disease pathology, and objective daytime sleepiness measured by the psychomotor vigilance task in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
301	Establishment of updated biomarker cutâ€off values for the secondâ€generation Elecsys βâ€amyloid(1–42), pTau and tTau CSF immunoassays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
302	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinsonâ \in^{TM} s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
303	CSF metabolites associated with CSF NeuroToolKit biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	1
304	Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling. Alzheimer's and Dementia, 2021, 17, .	0.4	0
305	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloidâ€positive individuals with subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
306	CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD. Alzheimer's and Dementia, 2021, 17, .	0.4	1

#	Article	IF	Citations
307	CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
308	Brain structural alterations in cognitively unimpaired individuals with discordant amyloida $\hat{\in}\hat{i}^2$ PET and CSF A \hat{i}^2 42 status: Findings using machine learning. Alzheimer's and Dementia, 2021, 17, .	0.4	0
309	Plasma glial fibrillary acidic protein is an early and specific marker of amyloidâ $\hat{\mathfrak{t}}^2$ pathology in Alzheimerâ \in ^M s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
310	Stress and Alzheimer's disease: Linking salivary cortisol to biomarkers of neurodegeneration and cognitive decline in a memory clinic cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	1
311	Recommendations of the International Working Group for the clinical diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
312	Amyloid time: Quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer $\hat{a} \in \mathbb{T}^M$ s disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	2
313	CSF amyloidâ€beta, tau, and neurodegenerative and inflammatory biomarkers in cognitively unimpaired late middleâ€aged and older adult <i>APOE ε4</i> homozygotes, heterozygotes, and nonâ€carriers from the Arizona APOE Cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	1
314	Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer $\hat{a} \in \mathbb{R}^{M}$ s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
315	Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer's continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
316	CSF biomarkers and blood pressure trajectories in normotensive individuals and subjects with controlled and uncontrolled hypertension. Alzheimer's and Dementia, 2021, 17, .	0.4	0
317	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
318	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer $\hat{a} \in \mathbb{T}^M$ s continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	2
319	Microstructural alterations in medial temporal and frontal white matter tracts are associated with subjective cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	0
320	Plasma pâ€ŧau231 in the Alzheimer's disease continuum: A multiâ€cohort evaluation of diagnostic performance, detection of Al² pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, .	0.4	0
321	Synergistic effects of CSF Aβ42 and pâ€Tau on functional restingâ€state connectivity in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
322	Distinctive effect of biological sex in ADâ€related CSF and plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	2
323	Dataâ€driven approach for early detection of pathological pathways in middleâ€aged adults with family history of sporadic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
324	Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of patients with mixed pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	Citations
325	Associations between plasma pâ \in tau217, in vivo brain pathology and cognition in individuals with autosomalâ \in dominant Alzheimerâ \in Ms disease: Findings from the Colombiaâ \in Boston (COLBOS) biomarker study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
326	Amyloid aggregation in temporal regions is associated with longitudinal memory decline in cognitively unimpaired <i>Apoe</i> $\hat{a} \in \hat{\mu}$ 4 carriers. Alzheimer's and Dementia, 2021, 17, .	0.4	0
327	Plasma pâ€Tau181 and pâ€Tau231 offer complementary information to identify Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	1
328	Associations between mean apparent propagator MRI and cerebrospinal fluid markers of AD pathology, neurodegeneration, and glial activation, in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
329	Apolipoprotein Îμ genotype modifies the association between bloodâ€brain barrier permeability and both grey and white matter integrity in older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
330	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching $\hat{l}^2\hat{a}\in a$ myloid biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	0
331	Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
332	Inflammatory biomarkers are associated with cerebral large artery thickening and dilatation in older adults. Alzheimer's and Dementia, $2021,17,.$	0.4	0
333	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
334	Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults. Alzheimer's and Dementia, $2021,17,.$	0.4	1
335	Alzheimer's disease genetic risk variants show brain cell typeâ€specific associations with protein levels in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, e049531.	0.4	0
336	Amyloid status is associated with deficits in connected speech language. Alzheimer's and Dementia, $2021,17,.$	0.4	0
337	Interactions between dietary patterns and genetic factors in relation to incident dementia among 70â€yearâ€olds. Alzheimer's and Dementia, 2021, 17, .	0.4	0
338	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middleâ \in aged adults with and without evidence of \hat{l}^2 â \in amyloid pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
339	Mass spectrometric measurement of six siteâ€specific tau phosphorylations in CSF and blood of Alzheimer's disease patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
340	Plasma pTau isoform assessment across disease stages. Alzheimer's and Dementia, 2021, 17, .	0.4	3
341	Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). Alzheimer's and Dementia, 2021, 17, .	0.4	3
342	CSF sTREM2 predicts markers of blood brain barrier integrity and amyloid beta metabolism independent of <i>APOEâ€Îµ4</i> status. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
343	Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2021, 17, .	0.4	O
344	Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation. Alzheimer's and Dementia, 2021, 17, .	0.4	0
345	Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a communityâ€based population of 70â€yearâ€olds. Alzheimer's and Dementia, 2021, 17, .	0.4	0
346	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, $2021,17,.$	0.4	0
347	Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
348	A novel antibody $\hat{a} \in \mathbb{R}$ ree mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, .	0.4	1
349	CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, .	0.4	4
350	Prediction of future Alzheimer's disease dementia using plasma phosphoâ€tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
351	Association of deepâ€learning–derived brain computed tomography measures with cognition and bloodâ€based biomarkers of neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, .	0.4	0
352	Diet and <i>APOE</i> as moderators of the relationship between trimethylamine Nâ€oxide and biomarkers of Alzheimer's disease and glial activation. Alzheimer's and Dementia, 2021, 17, e051827.	0.4	2
353	Impaired default mode network along with increased functional connectivity of the medial temporal lobe as a function of CSF pâ€₹au/Ab42 ratio in cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
354	Stability of the novel bloodâ€based biomarkers under preâ€analytical sample handling conditions: Results of the SABBâ€GBSC working group. Alzheimer's and Dementia, 2021, 17, .	0.4	0
355	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer $\hat{a} \in \mathbb{N}$ s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
356	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030.	0.4	0
357	A role for inflammaging in α-synuclein-associated breakdown of local sleep in the elderly Alzheimer's and Dementia, 2021, 17 Suppl 3, e054208.	0.4	0
358	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e055011.	0.4	0
359	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum Alzheimer's and Dementia, 2021, 17 Suppl 3, e055451.	0.4	0
360	CSF AÎ ² 42 and AÎ ² 40 and their relation to brain soluble and insoluble AÎ ² in the 5xFAD mouse model of Alzheimer's disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e055684.	0.4	0

#	Article	IF	Citations
361	The impact of social networks and <i>APOE</i> $\hat{l}\mu$ 4 on dementia among older adults: tests of possible interactions. Aging and Mental Health, 2020, 24, 395-404.	1.5	12
362	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	4.1	99
363	Acute symptomatic seizures and epilepsy after mechanical thrombectomy. Epilepsy and Behavior, 2020, 104, 106520.	0.9	25
364	Propagation of Tau Pathology: Integrating Insights From Postmortem and InÂVivo Studies. Biological Psychiatry, 2020, 87, 808-818.	0.7	50
365	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. Neurobiology of Aging, 2020, 86, 54-63.	1.5	136
366	Dementia and CSFâ€biomarkers for Alzheimer's disease predict mortality after acute hip fracture. Acta Anaesthesiologica Scandinavica, 2020, 64, 93-103.	0.7	19
367	Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 933-938.	1.8	4
368	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.4	47
369	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. Neurobiology of Disease, 2020, 134, 104645.	2.1	16
370	Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry, 2020, 152, 602-616.	2.1	15
371	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. BMC Neurology, 2020, 20, 10.	0.8	50
372	Neuroinflammatory markers associate with cognitive decline after major surgery: Findings of an explorative study. Annals of Neurology, 2020, 87, 370-382.	2.8	34
373	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	3.0	12
374	Circulating levels of vascular endothelial growth factor and postâ€stroke longâ€term functional outcome. Acta Neurologica Scandinavica, 2020, 141, 405-414.	1.0	8
375	Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men. Neurology, 2020, 94, e1181-e1189.	1.5	59
376	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	1.5	4
377	Glycan biomarkers for Alzheimer disease correlate with Tâ€ŧau and Pâ€ŧau in cerebrospinal fluid in subjective cognitive impairment. FEBS Journal, 2020, 287, 3221-3234.	2.2	36
378	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 3.	3.0	22

#	Article	IF	Citations
379	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.5	20
380	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain, 2020, 143, 650-660.	3.7	68
381	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Current Opinion in Neurobiology, 2020, 61, 29-39.	2.0	67
382	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. Clinica Chimica Acta, 2020, 502, 199-200.	0.5	0
383	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. Movement Disorders, 2020, 35, 513-518.	2.2	22
384	Postoperative delirium is associated with increased plasma neurofilament light. Brain, 2020, 143, 47-54.	3.7	107
385	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. Cerebral Cortex, 2020, 30, 2295-2306.	1.6	15
386	The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 911-919.	1.8	12
387	Quality of life of ice hockey players after retirement due to concussions. Concussion, 2020, 5, CNC78.	1.2	5
388	Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults. Frontiers in Neurology, 2020, 11, 1054.	1.1	45
389	Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 6864.	1.8	8
390	Biomarkers of neuronal damage in saturation divingâ€"a controlled observational study. European Journal of Applied Physiology, 2020, 120, 2773-2784.	1.2	3
391	β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	3.0	16
392	Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1429-1442.	1.5	4
393	Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. Clinical Microbiology and Infection, 2020, 27, 1131-1136.	2.8	15
394	Association of plasma YKL-40 with brain amyloid- \hat{l}^2 levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
395	Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. Brain Communications, 2020, 2, fcaa099.	1.5	9
396	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	3.0	20

#	Article	IF	CITATIONS
397	NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology, 2020, 95, e827-e838.	1.5	73
398	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. Brain, 2020, 143, 3793-3804.	3.7	60
399	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. Alzheimer's Research and Therapy, 2020, 12, 153.	3.0	9
400	Admission Levels of Interleukin 10 and Amyloid β 1–40 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury. Frontiers in Neurology, 2020, 11, 549527.	1.1	8
401	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
402	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147.	3.0	23
403	Fluid Biomarkers for Chronic Traumatic Encephalopathy. Seminars in Neurology, 2020, 40, 411-419.	0.5	14
404	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
405	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8Âyears prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	3.9	209
406	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. Neurobiology of Aging, 2020, 95, 143-153.	1.5	34
407	Reliability of serum S100B measurement following mild traumatic brain injury: a comparison of assay measurements from two laboratories. Brain Injury, 2020, 34, 1237-1244.	0.6	2
408	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
409	NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS. Multiple Sclerosis and Related Disorders, 2020, 46, 102463.	0.9	20
410	Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury. Scientific Reports, 2020, 10, 18075.	1.6	19
411	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. Brain Connectivity, 2020, 10, 555-565.	0.8	18
412	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. In Vivo, 2020, 34, 2577-2586.	0.6	17
413	Fatty Acid-Binding Protein 3 in Cerebrospinal Fluid of Hip Fracture Patients with Delirium. Journal of Alzheimer's Disease, 2020, 77, 183-190.	1.2	1
414	Cognitive Dispersion Is Not Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Results from the European Prevention of Alzheimer's Dementia (EPAD) v500.0 Cohort. Journal of Alzheimer's Disease, 2020, 78, 185-194.	1.2	5

#	Article	IF	CITATIONS
415	Neurofilament light chain in the vitreous humor of the eye. Alzheimer's Research and Therapy, 2020, 12, 111.	3.0	13
416	Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 77, 1129-1141.	1.2	55
417	First amyloid β1â€42 certified reference material for reâ€calibrating commercial immunoassays. Alzheimer's and Dementia, 2020, 16, 1493-1503.	0.4	42
418	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
419	Extensive Plasmid Library to Prepare Tau Protein Variants and Study Their Functional Biochemistry. ACS Chemical Neuroscience, 2020, 11, 3117-3129.	1.7	6
420	Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights, 2020, 15, 117727192095031.	1.0	74
421	Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus. Journal of NeuroVirology, 2020, 26, 719-726.	1.0	14
422	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. PLoS ONE, 2020, 15, e0233820.	1.1	8
423	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	3.9	39
424	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's <i>continuum</i> when only subtle changes in Aβ pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	3.3	202
425	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	3.0	7
426	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
427	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.4	0
428	Plasma Pâ€tau immunoassays, methodological aspects and clinical performance. Alzheimer's and Dementia, 2020, 16, e037515.	0.4	1
429	Phosphoâ€tau217 and phosphoâ€tau181 in plasma and CSF as biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037520.	0.4	2
430	Plasma phosphoâ€tau181 in over 400 cognitively healthy 69―to 71â€yearâ€olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. Alzheimer's and Dementia, 2020, 16, e037848.	0.4	0
431	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.4	0
432	Sex differences in CSF biomarkers for neurodegeneration and bloodâ€brain barrier integrity. Alzheimer's and Dementia, 2020, 16, e038588.	0.4	0

#	Article	IF	CITATIONS
433	Protective genetic variants in the MS4A gene cluster modulate microglial activity. Alzheimer's and Dementia, 2020, 16, e039431.	0.4	1
434	Reduction of neurogranin immunostaining in the hippocampus of postâ€mortem brain of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040707.	0.4	0
435	AD biomarker stability for stored CSF based on immunoassay results. Alzheimer's and Dementia, 2020, 16, e040747.	0.4	O
436	Associations of dietary patterns and CSF biomarkers for Alzheimer's disease in a populationâ€based sample of 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e040800.	0.4	0
437	CSF 7â€ketocholesterol is related to βâ€amyloid and white matter microstructure in healthy adults. Alzheimer's and Dementia, 2020, 16, e041015.	0.4	O
438	Selective association of neurogranin gene expression with amyloid and tau pathology in the parahippocampal gyrus in Alzheimer〙s disease. Alzheimer's and Dementia, 2020, 16, e041053.	0.4	0
439	An ultrasensitive immunoassay for detection of pâ€ŧau181 in blood. Alzheimer's and Dementia, 2020, 16, e041238.	0.4	1
440	Association of plasma YKLâ€40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. Alzheimer's and Dementia, 2020, 16, e041753.	0.4	0
441	Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains. Alzheimer's and Dementia, 2020, 16, e042479.	0.4	O
442	Research diagnostic criteria for Alzheimer's disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530.	0.4	0
443	A novel proteomics assay allows parallel quantitation of a panel of synaptic proteins in human cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e042578.	0.4	O
444	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e042955.	0.4	0
445	Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer's disease from healthy controls. Alzheimer's and Dementia, 2020, 16, e043467.	0.4	1
446	The interaction of amyloid and tau on decreased cortical neurite density in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043979.	0.4	0
447	CSF NFL levels and neuroimagingâ€derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the Alzheimer's pathologic framework. Alzheimer's and Dementia, 2020, 16, e043987.	0.4	2
448	Elevated levels of synaptic protein GAPâ€43 associate with brain tauopathy, atrophy and cognition in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044098.	0.4	2
449	Amyloidâ€Î², tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044444.	0.4	О
450	Emerging betaâ€amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer's and Dementia, 2020, 16, e044466.	0.4	1

#	Article	IF	CITATIONS
451	Cerebrospinal fluid levels of SNAPâ€25 and SYT1 in Alzheimer's and Parkinson's disease. Alzheimer's and Dementia, 2020, 16, e044515.	0.4	3
452	Genetically predicted telomere length and Alzheimer's disease endophenotypes: A Mendelian randomization study. Alzheimer's and Dementia, 2020, 16, e044720.	0.4	0
453	The effect of physical activity on CSF biomarkers of Alzheimer's disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722.	0.4	0
454	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044733.	0.4	0
455	Higher frontoâ€parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. Alzheimer's and Dementia, 2020, 16, e044780.	0.4	O
456	Air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. Alzheimer's and Dementia, 2020, 16, e044802.	0.4	3
457	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044808.	0.4	O
458	APOE ―Îμ4 shapes temporoâ€parietal network properties in middleâ€aged, cognitively unimpaired individuals: A graph theory analysis. Alzheimer's and Dementia, 2020, 16, e045092.	0.4	0
459	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middleâ€aged adults. Alzheimer's and Dementia, 2020, 16, e045137.	0.4	O
460	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. Alzheimer's and Dementia, 2020, 16, e045171.	0.4	0
461	Incidence of subjective cognitive decline is associated with amyloid $\hat{\mathbf{e}}^2$ pathology, whereas stability relates to neurodegeneration. Alzheimer's and Dementia, 2020, 16, e045293.	0.4	O
462	CSF phosphorylated tauâ€217 is increased in Alzheimer's and Creutzfeldtâ€Jakob diseases and correlates with amyloid pathology. Alzheimer's and Dementia, 2020, 16, e045296.	0.4	4
463	Amyloidâ€positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. Alzheimer's and Dementia, 2020, 16, e045715.	0.4	O
464	Impact of APOE â€îµ4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e045828.	0.4	1
465	DNA methylation differences associated with peripheral biomarkers in the EMIFâ€AD cohort. Alzheimer's and Dementia, 2020, 16, e045853.	0.4	O
466	Levels of amyloid β in cerebrospinal fluid predicts cognition five years later: A populationâ€based study of 70â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e045969.	0.4	0
467	Multimodal genomeâ€wide metaâ€analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. Alzheimer's and Dementia, 2020, 16, e046009.	0.4	О
468	Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065.	0.4	1

#	Article	IF	CITATIONS
469	Baseline cerebrospinal fluid biomarkers of amyloidosis, phosphorylated tau, and total tau relate to greater longitudinal atrophy in regions susceptible to Alzheimerâ∈™s diseaseâ€related neurodegeneration. Alzheimer's and Dementia, 2020, 16, e046095.	0.4	0
470	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. Alzheimer's and Dementia, 2020, 16, e046102.	0.4	0
471	Microglial activation indexed by [11 C]PBR28 is associated with synaptic depletion in the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2020, 16, e046191.	0.4	0
472	Hypertension accentuates reductions in CSF A \hat{l}^2 42 in elderly depressives. Alzheimer's and Dementia, 2020, 16, e046299.	0.4	0
473	Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum. Alzheimer's and Dementia, 2020, 16, e046355.	0.4	o
474	SNAP25 reflects amyloid―and tauâ€related synaptic damage: Associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2020, 16, e046358.	0.4	3
475	Exploring genetic contributors to neuroprotection from AD pathologies: A genomeâ€wide association study. Alzheimer's and Dementia, 2020, 16, e046417.	0.4	O
476	Cerebrospinal fluid phosphorylated tau interacts with MMP2 and MMP3: Associations with cognitive performance in older adults. Alzheimer's and Dementia, 2020, 16, e046463.	0.4	0
477	Plasmaâ€based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.4	o
478	Bloodâ€brain barrier permeability measured by 7αâ€hydroxyâ€3â€oxoâ€4â€cholestenoic acid in CSF associates v Alzheimer's pathology biomarkers in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e046582.	with 0.4	0
479	Insulin resistance is related to cognitive decline but not biomarkers of Alzheimer's pathology in adults without dementia. Alzheimer's and Dementia, 2020, 16, e047022.	0.4	O
480	Longitudinal changes in established and exploratory cerebrospinal fluid biomarkers by PTAU/AÎ ² 42 status in cognitively unimpaired adults. Alzheimer's and Dementia, 2020, 16, e047156.	0.4	0
481	CSF proteomic profiling of mild cognitive impairment individuals with suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2020, 16, e047247.	0.4	1
482	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routineâ€use protocol for CSF collection. Alzheimer's and Dementia, 2020, 16, e047394.	0.4	0
483	Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay. Alzheimer's and Dementia, 2020, 16, e047517.	0.4	0
484	Plasma pâ€tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to postâ€mortem and improves the clinical characterisation of cognitive decline. Alzheimer's and Dementia, 2020, 16, e047539.	0.4	2
485	Alzheimer's pathologic change indexed by CSF Bâ€amyloid42 associates with longitudinal alterations in myelin content. Alzheimer's and Dementia, 2020, 16, e047629.	0.4	O
486	Ultraâ€performance liquid chromatographyâ€ŧandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture. Alzheimer's and Dementia, 2020, 16, e040373.	0.4	0

#	Article	IF	Citations
487	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, $2020,11,6252.$	5.8	36
488	Steroidâ€Responsive Encephalitis in Coronavirus Disease 2019. Annals of Neurology, 2020, 88, 423-427.	2.8	230
489	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. Acta Neurologica Scandinavica, 2020, 142, 161-168.	1.0	2
490	Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage. Journal of Alzheimer's Disease, 2020, 74, 1143-1156.	1.2	7
491	Cerebrospinal Fluid Biomarkers to Differentiate Idiopathic Normal Pressure Hydrocephalus from Subcortical Ischemic Vascular Disease. Journal of Alzheimer's Disease, 2020, 75, 937-947.	1.2	13
492	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 883-895.	0.4	10
493	Losing the identity of a hockey player: the long-term effects of concussions. Concussion, 2020, 5, CNC74.	1.2	4
494	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. Neurobiology of Aging, 2020, 94, 60-70.	1.5	35
495	Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. Lancet Neurology, The, 2020, 19, 513-521.	4.9	97
496	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
497	Human plasma biomarker responses to inhalational general anaesthesia without surgery. British Journal of Anaesthesia, 2020, 125, 282-290.	1.5	27
498	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i> . Alzheimer's and Dementia, 2020, 16, 1358-1371.	0.4	120
499	Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease, 2020, 76, 941-953.	1.2	9
500	Blood Biomarkers: Democratizing Alzheimer's Diagnostics. Neuron, 2020, 106, 881-883.	3.8	38
501	Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury. Frontiers in Neurology, 2020, 11, 325.	1.1	11
502	Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences. Frontiers in Aging Neuroscience, 2020, 12, 139.	1.7	4
503	Dextran- Versus Crystalloid-Based Prime in Cardiac Surgery: A Prospective Randomized Pilot Study. Annals of Thoracic Surgery, 2020, 110, 1541-1547.	0.7	12
504	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology, 2020, 95, e1754-e1759.	1.5	304

#	Article	IF	CITATIONS
505	Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-Î ² 42 and White Matter Microstructure in Cognitively Healthy Adults. Journal of Alzheimer's Disease, 2020, 76, 643-656.	1.2	8
506	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15
507	Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury. Frontiers in Neurology, 2020, 11, 376.	1.1	20
508	Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Medicine, 2020, 18, 140.	2.3	34
509	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	1.1	14
510	Low CSF/serum ratio of free T4 is associated with decreased quality of life in mild hypothyroidism – A pilot study. Journal of Clinical and Translational Endocrinology, 2020, 19, 100218.	1.0	4
511	APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. Cerebral Cortex, 2020, 30, 4110-4120.	1.6	7
512	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 21.	3.0	183
513	Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression. Cerebral Cortex, 2020, 30, 2144-2156.	1.6	13
514	Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults. Journal of Alzheimer's Disease, 2020, 74, 965-974.	1.2	14
515	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology, 2020, 95, e953-e961.	1.5	50
516	CSF levels of synaptosomal-associated protein 25 and synaptotagmin-1 in first-episode psychosis subjects. IBRO Reports, 2020, 8, 136-142.	0.3	5
517	Diagnostic and prognostic value of serum NfL and p-Tau ₁₈₁ in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 960-967.	0.9	93
518	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-Î ² Load. Journal of Alzheimer's Disease, 2020, 76, 291-301.	1.2	3
519	CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: a comparative study. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115095.	0.8	2
520	Neurofilament light as a biomarker in traumatic brain injury. Neurology, 2020, 95, e610-e622.	1.5	127
521	Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI. Neurology, 2020, 95, e623-e636.	1.5	136
522	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643

#	Article	IF	CITATIONS
523	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
524	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	1.5	15
525	Accelerated neuronal and synaptic maturation by BrainPhys medium increases $\hat{A^2}$ secretion and alters $\hat{A^2}$ peptide ratios from iPSC-derived cortical neurons. Scientific Reports, 2020, 10, 601.	1.6	26
526	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	3.0	32
527	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	3.0	29
528	Contribution of CSF biomarkers to earlyâ€onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Human Brain Mapping, 2020, 41, 2004-2013.	1.9	22
529	Cerebrospinal Fluid Levels of Interleukin-8 in Delirium, Dementia, and Cognitively Healthy Patients. Journal of Alzheimer's Disease, 2020, 73, 1363-1372.	1.2	18
530	Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Archives of Toxicology, 2020, 94, 2517-2522.	1.9	43
531	Neurofilamentâ€light in former athletes: a potential biomarker of neurodegeneration and progression. European Journal of Neurology, 2020, 27, 1170-1177.	1.7	12
532	AÎ ² deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
533	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	4.9	121
534	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
535	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiology of Aging, 2020, 93, 1-15.	1.5	11
536	Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. Journal of Alzheimer's Disease, 2020, 74, 1211-1220.	1.2	22
537	Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy. Frontiers in Neurology, 2020, 11, 586610.	1.1	4
538	Steroid-Responsive Encephalitis in Coronavirus Disease 2019., 2020, 88, 423.		1
539	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12099.	1.2	16
540	Preâ€analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12137.	1.2	20

#	Article	IF	Citations
541	Genome-wide study of immune biomarkers in cerebrospinal fluid and serum from patients with bipolar disorder and controls. Translational Psychiatry, 2020, 10, 58.	2.4	8
542	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
543	Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. Scientific Reports, 2020, 10, 22400.	1.6	6
544	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
545	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 617-625.	0.9	19
546	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.5	31
547	Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia. PLoS ONE, 2020, 15, e0236384.	1.1	23
548	Untangling the roles of amyloid and tau in synaptic and axonal loss in the course of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043169.	0.4	1
549	Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease. Alzheimer's and Dementia, 2020, 16, e043060.	0.4	O
550	White matter microstructure and cerebrospinal fluid biomarkers of Alzheimer's disease in middleâ€aged cognitively unimpaired participants (the ALFA study). Alzheimer's and Dementia, 2020, 16, e043027.	0.4	0
551	Title is missing!. , 2020, 17, e1003289.		O
552	Title is missing!. , 2020, 17, e1003289.		0
553	Title is missing!. , 2020, 17, e1003289.		0
554	Title is missing!. , 2020, 17, e1003289.		0
555	Title is missing!. , 2020, 17, e1003289.		О
556	Title is missing!. , 2020, 17, e1003289.		0
557	Title is missing!. , 2020, 17, e1003289.		0
558	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0

#	Article	IF	Citations
559	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		O
560	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0
561	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820.		0
562	Title is missing!. , 2020, 15, e0236384.		0
563	Title is missing!. , 2020, 15, e0236384.		0
564	Title is missing!. , 2020, 15, e0236384.		0
565	Title is missing!. , 2020, 15, e0236384.		0
566	Molecular imaging mass spectrometry for probing protein dynamics in neurodegenerative disease pathology. Journal of Neurochemistry, 2019, 151, 488-506.	2.1	34
567	Antibodyâ€based methods for the measurement of αâ€synuclein concentration in human cerebrospinal fluid – method comparison and round robin study. Journal of Neurochemistry, 2019, 149, 126-138.	2.1	44
568	Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. Neuropsychobiology, 2019, 77, 13-22.	0.9	20
569	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion, 2019, 46, 228-235.	1.6	10
570	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Science Translational Medicine, 2019, 11, .	5.8	170
571	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 228-232.	0.9	20
572	Circulating neurofilament light in ischemic stroke: temporal profile and outcome prediction. Journal of Neurology, 2019, 266, 2796-2806.	1.8	49
573	Plasma neurofilament light chain concentration is increased in anorexia nervosa. Translational Psychiatry, 2019, 9, 180.	2.4	26
574	Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 71, 775-783.	1.2	38
575	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9
576	Plasma tau complements CSF tau and Pâ€tau in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 483-492.	1,2	86

#	Article	IF	Citations
577	Characterization of Cerebrospinal Fluid BACE1 Species. Molecular Neurobiology, 2019, 56, 8603-8616.	1.9	4
578	Sex differences in the genetic predictors of Alzheimer's pathology. Brain, 2019, 142, 2581-2589.	3.7	65
579	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. Acta Neuropathologica Communications, 2019, 7, 120.	2.4	64
580	Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease. Brain Research, 2019, 1720, 146305.	1.1	34
581	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. NeuroImage: Clinical, 2019, 23, 101895.	1.4	28
582	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1556-1564.	1.4	32
583	Chemometric Strategies for Sensitive Annotation and Validation of Anatomical Regions of Interest in Complex Imaging Mass Spectrometry Data. Journal of the American Society for Mass Spectrometry, 2019, 30, 2278-2288.	1.2	11
584	Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease. Journal of Neuroinflammation, 2019, 16, 186.	3.1	41
585	Autocatalytic amplification of Alzheimer-associated Al 2 42 peptide aggregation in human cerebrospinal fluid. Communications Biology, 2019, 2, 365.	2.0	46
586	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 72, 525-535.	1.2	16
587	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€ŧau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
588	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	3.3	228
589	Detection of early-stage Alzheimer's pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients. PLoS ONE, 2019, 14, e0225178.	1.1	12
590	Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 700-709.	1.2	35
591	"Alzheimer's disease―is neither "Alzheimer's clinical syndrome―nor "dementia― Alzheimer's and Dementia, 2019, 15, 153-157.	0.4	23
592	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Communications, 2019, 7, 5.	2.4	125
593	Was it worth it? Older adults' experiences of participating in a population-based cohort study – a focus group study. BMC Geriatrics, 2019, 19, 224.	1.1	13
594	Growth factors and neurotrophins in patients with stress-related exhaustion disorder. Psychoneuroendocrinology, 2019, 109, 104415.	1.3	15

#	Article	IF	Citations
595	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
596	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	1.5	48
597	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. Alzheimer's Research and Therapy, 2019, 11, 82.	3.0	51
598	CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimer's Research and Therapy, 2019, 11, 81.	3.0	72
599	Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2019, 71, 281-290.	1.2	7
600	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloidâ€positive individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 679-689.	1.2	48
601	Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. Infectious Diseases, 2019, 51, 838-846.	1.4	7
602	Age-Dependent Relationship Between Plasma A \hat{l}^2 40 and A \hat{l}^2 42 and Total Tau Levels in Cognitively Normal Subjects. Frontiers in Aging Neuroscience, 2019, 11, 222.	1.7	29
603	NFL blood levels are moderated by subconcussive impacts in a cohort of college football players. Brain Injury, 2019, 33, 456-462.	0.6	50
604	Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. Journal of Neuroinflammation, 2019, 16, 16.	3.1	22
605	Head trauma in sports and risk for dementia. Journal of Internal Medicine, 2019, 285, 591-593.	2.7	3
606	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
607	Elecsys \hat{A}^{\otimes} Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
608	Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	0.8	30
609	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
610	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
611	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1117-1123.	0.9	61
612	NFL is a marker of treatment response in children with SMA treated with nusinersen. Journal of Neurology, 2019, 266, 2129-2136.	1.8	104

#	Article	IF	CITATIONS
613	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. Journal of Neurology, 2019, 266, 2157-2163.	1.8	41
614	Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women. Neurobiology of Aging, 2019, 80, 111-115.	1.5	6
615	Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2242-2249.	0.7	40
616	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
617	Plasma and CSF neurofilament light. Neurology, 2019, 93, e252-e260.	1.5	160
618	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 1213-1220.	1.2	12
619	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2019, 76, 969.	4.5	65
620	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
621	Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism. Acta Neurologica Scandinavica, 2019, 140, 147-156.	1.0	15
622	Plasma amyloid \hat{l}^2 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.4	122
623	Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 551-559.	1.2	6
624	Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapyâ€"A pilot study. Journal of Affective Disorders, 2019, 253, 449-453.	2.0	17
625	Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. Acta Neurologica Scandinavica, 2019, 140, 177-183.	1.0	3
626	A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2850-2862.	1.7	129
627	CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 846-853.	0.9	46
628	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 129-138.	1.8	22
629	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	4.5	436
630	Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain. Brain, 2019, 142, 1441-1457.	3.7	74

#	Article	IF	Citations
631	Atrial fibrillation increases the risk of dementia amongst older adults even in the absence of stroke. Journal of Internal Medicine, 2019, 286, 101-110.	2.7	23
632	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	3.0	82
633	Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Clinica Chimica Acta, 2019, 494, 79-93.	0.5	30
634	Serum Neurofilament Light Is Elevated Differentially in Older Adults with Uncomplicated Mild Traumatic Brain Injuries. Journal of Neurotrauma, 2019, 36, 2400-2406.	1.7	27
635	Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. PLoS ONE, 2019, 14, e0212815.	1.1	12
636	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
637	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.4	82
638	Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid- \hat{l}^2 and tau. Neurobiology of Aging, 2019, 80, 11-20.	1.5	80
639	Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 870-881.	0.9	623
640	Amyloid \hat{l}^2 42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death. Dementia and Geriatric Cognitive Disorders, 2019, 47, 114-124.	0.7	3
641	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1565-1573.	1.4	11
642	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	0.9	23
643	Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort. Journal of Alzheimer's Disease, 2019, 69, 111-121.	1.2	8
644	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	4.9	393
645	APOEÎ μ 4 and the long arm of social inequity: estimated effects of socio-economic status and sex on the timing of dementia onset. Ageing and Society, 2019, 39, 1951-1975.	1.2	6
646	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	1.5	23
647	Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease. Journal of Proteome Research, 2019, 18, 2109-2120.	1.8	49
648	Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer's disease patients. Scientific Reports, 2019, 9, 5522.	1.6	20

#	Article	IF	Citations
649	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	1.6	7
650	Increased Secondary Nucleation Underlies Accelerated Aggregation of the Four-Residue N-Terminally Truncated Aβ42 Species Aβ5–42. ACS Chemical Neuroscience, 2019, 10, 2374-2384.	1.7	16
651	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 19.	3.0	65
652	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Molecular and Cellular Neurosciences, 2019, 97, 34-42.	1.0	55
653	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10.	4.4	61
654	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Science Advances, 2019, 5, eaau7220.	4.7	59
655	Neurogranin as a potential synaptic marker in the cerebrospinal fluid of patients with a first episode psychosis. Schizophrenia Research, 2019, 208, 490-492.	1.1	5
656	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. Cellular and Molecular Life Sciences, 2019, 76, 1833-1863.	2.4	75
657	Measuring longitudinal cognition: Individual tests versus composites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 74-84.	1.2	69
658	Sleep deprivation and plasma biomarkers for Alzheimer's disease. Sleep Medicine, 2019, 57, 92-93.	0.8	8
659	Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurologica Scandinavica, 2019, 139, 462-468.	1.0	21
660	Peptidomic analysis of cartilage and subchondral bone in OA patients. European Journal of Clinical Investigation, 2019, 49, e13082.	1.7	6
661	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer's disease. Neuroscience Letters, 2019, 701, 125-131.	1.0	43
662	Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. Journal of Biological Chemistry, 2019, 294, 6719-6732.	1.6	49
663	Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 2178-2189.	1.7	56
664	FTS3â€01â€01: UMIBECESTAT (CNP520) IS NOT ASSOCIATED WITH CHANGES IN HIPPOCAMPAL MORPHOLOGY RATS OR CHANGES IN CSF AD BIOMARKERS IN HUMANS TREATED FOR 3 MONTHS. Alzheimer's and Dementia, 2019, 15, P872.	IN 0.4	1
665	P4â€531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO βâ€AMYLOII POSITIVITY. Alzheimer's and Dementia, 2019, 15, P1517.	D 0.4	O
666	P4â€546: THE NEURAL CELL ADHESION PROTEIN NEUROLIGIN 1 IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1526.	0.4	O

#	Article	IF	Citations
667	P4â€579: LOWER NEURITE DENSITY AND ORIENTATION DISPERSION WITHIN GRAY AND WHITE MATTER IN THE ALZHEIMER'S DISEASE PATHOLOGIC FRAMEWORK. Alzheimer's and Dementia, 2019, 15, P1542.	0.4	0
668	Altered CSF levels of monoamines in hereditary spastic paraparesis 10. Neurology: Genetics, 2019, 5, e344.	0.9	2
669	CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. Alzheimer's Research and Therapy, 2019, 11, 105.	3.0	31
670	P4â€573: PROXIMITY TO PARENTAL ONSET AND <i>APOE</i> ε4 INDEPENDENTLY CONTRIBUTE TO AMYLOID BURDEN IN MIDDLEâ€AGED ADULTS WITH A FAMILY HISTORY OF SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1539.	0.4	О
671	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.4	0
672	CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1.0 Neurology: Neuroimmunology and NeuroInflammation, $2019, 6,$	3.1	7
673	O3â€02â€01: APOE <i>àê€</i> jµ4 ALLELIC LOAD MODULATES THE ASSOCIATION BETWEEN CSF BETAâ€AMYLOID MATTER VOLUME IN COGNITIVELY UNIMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P877.	AND GRAY	o'
674	F4â€05â€01: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1224.	0.4	0
675	P4â€473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX Aβ PEPTIDES HUMAN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1492.	IN _{0.4}	О
676	P4â€535: PRESENTATION OF A ROUTINEâ€USE PREâ€ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS. Alzheimer's and Dementia, 2019, 15, P1520.	0.4	0
677	P4â€589: COMPARISON OF CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CHAIN PROTEIN AND THREE MRIâ€BASED MORPHOMETRIC ESTIMATES FOR DEFINING NEURODEGENERATION (N) ACROSS THE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2019, 15, P1547.	0.4	O
678	O2â€05â€01: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer and Dementia, 2019, 15, P545.	['] ်၀.4	2
679	ICâ€Pâ€093: PLASMA AMYLOIDâ€BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDICT CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD. Alzheimer's and Dementia, 2019, 15, P82.	0.4	O
680	Complement component 3 levels in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder. Biomarkers in Neuropsychiatry, 2019, 1, 100007.	0.7	10
681	P4â€519: MOLECULAR FORMS OF NEUROGRANIN IN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 19 P1513.	⁵ o.4	O
682	ICâ€Pâ€070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P64.	0.4	1
683	ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P65.	0.4	O
684	ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXELâ€BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P66.	0.4	0

#	Article	IF	CITATIONS
685	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
686	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM<td>ⁱ∂.4</td><td>0</td></i>	ⁱ ∂.4	0
687	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimer's Research and Therapy, 2019, 11, 94.	3.0	20
688	Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Progress in Molecular Biology and Translational Science, 2019, 168, 3-23.	0.9	28
689	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. Scientific Reports, 2019, 9, 17309.	1.6	5
690	Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328
691	Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep. PLoS ONE, 2019, 14, e0226697.	1.1	17
692	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
693	Repeated lumbar punctures within 3Âdays may affect CSF biomarker levels. Fluids and Barriers of the CNS, 2019, 16, 37.	2.4	8
694	Salivary Biomarkers for Alzheimer's Disease and Related Disorders. Neurology and Therapy, 2019, 8, 83-94.	1.4	54
695	Peripheral Biomarkers for Alzheimer's Disease: Update and Progress. Neurology and Therapy, 2019, 8, 33-36.	1.4	7
696	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	1.0	82
697	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	2.1	11
698	Neurofilament changes in serum and cerebrospinal fluid after acute ischemic stroke. Neuroscience Letters, 2019, 698, 58-63.	1.0	57
699	The Gothenburg H70 Birth cohort study 2014–16: design, methods and study population. European Journal of Epidemiology, 2019, 34, 191-209.	2.5	89
700	Head trauma in sports – clinical characteristics, epidemiology and biomarkers. Journal of Internal Medicine, 2019, 285, 624-634.	2.7	39
701	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	4.5	66
702	The recency ratio is related to CSF amyloid beta 1â€42 levels in MClâ€AD. International Journal of Geriatric Psychiatry, 2019, 34, 415-419.	1.3	12

#	Article	IF	CITATIONS
703	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. Current HIV/AIDS Reports, 2019, 16, 76-81.	1.1	9
704	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1152-1163.	3.3	30
705	Association of PTHrP levels in CSF with Alzheimer's disease biomarkers. Clinical Mass Spectrometry, 2019, 14, 124-129.	1.9	5
706	Accurate risk estimation of βâ€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
707	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurology, 2019, 76, 64.	4.5	158
708	Elevated CSF GAPâ€43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
709	Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurologica Scandinavica, 2019, 139, 172-176.	1.0	18
710	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	1.0	163
711	Cerebrospinal fluid biomarkers of neurofibrillary tangles and synaptic dysfunction are associated with longitudinal decline in white matter connectivity: A multi-resolution graph analysis. NeuroImage: Clinical, 2019, 21, 101586.	1.4	24
712	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. Acta Neuropathologica, 2019, 137, 279-296.	3.9	128
713	The 12-Word Philadelphia Verbal Learning Test Performances in Older Adults: Brain MRI and Cerebrospinal Fluid Correlates and Regression-Based Normative Data. Dementia and Geriatric Cognitive Disorders Extra, 2019, 8, 476-491.	0.6	7
714	Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 1551-1560.	1.7	56
715	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
716	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. Neuroscience, 2019, 420, 136-144.	1.1	25
717	Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434.	2.1	15
718	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. Acta Neuropathologica, 2019, 137, 89-102.	3.9	64
719	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 458-467.	1.1	30
720	Association of longitudinal white matter degeneration and cerebrospinal fluid biomarkers of neurodegeneration, inflammation and Alzheimer's disease in late-middle-aged adults. Brain Imaging and Behavior, 2019, 13, 41-52.	1.1	32

#	Article	IF	CITATIONS
721	Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas. World Journal of Oncology, 2019, 10, 169-175.	0.6	28
722	Title is missing!. , 2019, 14, e0226276.		0
723	Title is missing!. , 2019, 14, e0226276.		0
724	Title is missing!. , 2019, 14, e0226276.		0
725	Title is missing!. , 2019, 14, e0226276.		0
726	Moderate intensity physical activity associates with CSF biomarkers in a cohort at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 188-195.	1.2	51
727	Induction of Amyloid- \hat{l}^2 42 Production by Fipronil and Other Pyrazole Insecticides. Journal of Alzheimer's Disease, 2018, 62, 1663-1681.	1.2	23
728	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry, 2018, 64, 927-937.	1.5	37
729	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468
730	Low Cerebrospinal Fluid A $\hat{1}^2$ 42 and A $\hat{1}^2$ 40 are Related to White Matter Lesions in Cognitively Normal Elderly. Journal of Alzheimer's Disease, 2018, 62, 1877-1886.	1.2	13
731	Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology, 2018, 90, e1780-e1788.	1.5	147
732	Cerebrospinal fluid markers of extracellular matrix remodelling, synaptic plasticity and neuroinflammation before and after cranial radiotherapy. Journal of Internal Medicine, 2018, 284, 211-225.	2.7	12
733	Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. Journal of Neurotrauma, 2018, 35, 2351-2356.	1.7	43
734	Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1857-1863.	1.2	100
735	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
736	Association of Plasma Neurofilament Light Chain with Neocortical Amyloid- \hat{l}^2 Load and Cognitive Performance in Cognitively Normal Elderly Participants. Journal of Alzheimer's Disease, 2018, 63, 479-487.	1.2	50
737	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2018, 9, 1802-1817.	1.7	60
738	Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. Acta Neurologica Scandinavica, 2018, 138, 143-150.	1.0	24

#	Article	IF	CITATIONS
739	The Past and the Future of Alzheimer's Disease Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 62, 1125-1140.	1.2	106
740	Prevalence of preclinical Alzheimer disease. Neurology, 2018, 90, e1682-e1691.	1.5	82
741	Association of Changes in Plasma Neurofilament Light and Tau Levels With Anesthesia and Surgery. JAMA Neurology, 2018, 75, 542.	4.5	96
742	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.4	61
743	Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. EBioMedicine, 2018, 28, 21-30.	2.7	250
744	Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. Journal of Alzheimer's Disease, 2018, 62, 385-397.	1.2	81
745	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology, 2018, 90, e877-e886.	1.5	28
746	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2018, 62, 417-427.	1.2	5
747	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.5	65
748	Genetic Variation in FOXO3 is Associated with Self-Rated Health in a Population-Based Sample of Older Individuals. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1453-1458.	1.7	10
749	Sleep deprivation and cerebrospinal fluid biomarkers for Alzheimer's disease. Sleep, 2018, 41, .	0.6	73
750	Evolution of cerebrospinal fluid total \hat{l}_{\pm} -synuclein in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 49, 4-8.	1.1	31
751	Cerebrospinal Fluid S100B and Alzheimer's Disease Biomarkers in Hip Fracture Patients with Delirium. Dementia and Geriatric Cognitive Disorders Extra, 2018, 7, 374-385.	0.6	31
752	Comparing ¹⁸ F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.5	83
753	Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology, 2018, 90, e518-e524.	1.5	176
754	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology, 2018, 5, 162-171.	1.7	30
7 55	Alzheimer's disease biomarkerâ€guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Al² _{1–42} , totalâ€ŧau, phosphorylatedâ€ŧau, NFL, neurogranin, and YKLâ€40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.4	91
756	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain, 2018, 141, 459-471.	3.7	143

#	Article	IF	Citations
757	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimer's Research and Therapy, 2018, 10, 8.	3.0	111
758	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
759	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
760	Cerebrospinal fluid \hat{l}^2 -amyloid42 and neurofilament light relate to white matter hyperintensities. Neurobiology of Aging, 2018, 68, 18-25.	1.5	39
761	Prevalence of the apolipoprotein E $\hat{l}\mu4$ allele in amyloid \hat{l}^2 positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
762	Apolipoprotein E genotypes and longevity across dementia disorders. Alzheimer's and Dementia, 2018, 14, 895-901.	0.4	8
763	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. Scientific Reports, 2018, 8, 4260.	1.6	25
764	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. Biological Psychiatry, 2018, 83, 447-455.	0.7	83
765	Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Multiple Sclerosis Journal, 2018, 24, 1046-1054.	1.4	149
766	Neuroinflammation and Tau Interact with Amyloid in Predicting Sleep Problems in Aging Independently of Atrophy. Cerebral Cortex, 2018, 28, 2775-2785.	1.6	40
767	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
768	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. Proteomics - Clinical Applications, 2018, 12, 1700131.	0.8	87
769	Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease. Acta Neurologica Scandinavica, 2018, 137, 91-98.	1.0	20
770	Inhibition of \hat{I}^3 -Secretase Leads to an Increase in Presenilin-1. Molecular Neurobiology, 2018, 55, 5047-5058.	1.9	19
771	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
772	CSF neurofilament light concentration is increased in presymptomatic <i>CHMP2B</i> mutation carriers. Neurology, 2018, 90, e157-e163.	1.5	11
773	Increased midlife triglycerides predict brain \hat{l}^2 -amyloid and tau pathology 20 years later. Neurology, 2018, 90, e73-e81.	1.5	76
774	Central and peripheral leptin and agoutiâ€related protein during and after pregnancy in relation to weight change. Clinical Endocrinology, 2018, 88, 263-271.	1.2	9

#	Article	IF	CITATIONS
775	Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 933-943.	2.5	174
776	O2â€03â€05: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED, LATE MIDDLEâ€AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P617.	0.4	0
777	P3â€218: NOVEL ALZHEIMER'S DISEASE BIOMARKERâ€GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VAI OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: Aβ _{1â€42} , TOTALâ€TAU, PHOSPHORYLATEDâ€TAU, NFL, NEUROGRANIN, AND YKLâ€40. Alzheimer's and Dementia, 2018, 14, P1154.		1
778	P3â€161: ALTERATIONS IN ALZHEIMERâ€ASSOCIATED SYNAPTIC MARKERS FOLLOWING IRRADIATION OF STEM CELLâ€DERIVED CORTICAL NEURONS. Alzheimer's and Dementia, 2018, 14, P1129.	0.4	0
779	P3â€267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P1178.	0.4	1
780	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.4	0
781	P2â€273: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AND RISK OF MILD COGNITIVE IMPAIRMENT IN THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2018, 14, P782.	0.4	0
782	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.4	0
783	P1â€007: POOR SLEEP IS ASSOCIATED WITH CSFâ€MARKERS OF ALZHEIMER'S DISEASE IN 70â€YEARâ€OLDS WI DEMENTIA. Alzheimer's and Dementia, 2018, 14, P265.	тноит 6.4	0
784	F2â€02â€01: NEUROFILAMENT LIGHT CHAIN IN AD IN CSF AND BLOOD. Alzheimer's and Dementia, 2018, 14, P60	3. 4	0
785	ICâ€Pâ€018: VERBAL FLUENCY MEASURES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY UNIMPAIRED LATE MIDDLEâ€AGED ADULTS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. Alzheimer's and Dementia, 2018, 14, P23.	0.4	2
786	P1â€217: PROTEOLYTIC PROCESSING OF THE SYNAPTIC ALZHEIMER BIOMARKER NEUROGRANIN BY CALPAIN I AND PROLYL ENDOPEPTIDASE. Alzheimer's and Dementia, 2018, 14, P361.	0.4	0
787	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	O
788	P1â€279: BIMODAL DISTRIBUTION OF THE CSF Aβ42/Aβ40 RATIO IN CLINICAL LABORATORY PRACTICE. Alzheime and Dementia, 2018, 14, P389.	r's 0.4	0
789	P1â€026: CEREBROSPINAL FLUID TAU, Aβ, AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. Alzheimer's and Dementia, 2018, 14, P275.	0.4	O
790	Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurology, 2018, 18, 202.	0.8	21
791	D10â€Neurofilament light protein in blood predicts regional atrophy in huntington's disease. , 2018, , .		O
792	P2â€237: ASSOCIATION OF CSF ALPHA‧YNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTIC STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762.		0

#	Article	IF	CITATIONS
793	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036.	0.4	O
794	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEAS DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510.	E _{0.4}	0
795	P1â€262: NEUROFILAMENT LIGHT PROTEIN IS ASSOCIATED WITH COGNITIVE DECLINE WITHIN THE ATN MODEL. Alzheimer's and Dementia, 2018, 14, P381.	0.4	O
796	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.4	0
797	Chronic traumatic encephalopathy: fluid biomarkers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 158, 323-333.	1.0	14
798	CSF sTREM2 in deliriumâ€"relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau. Journal of Neuroinflammation, 2018, 15, 304.	3.1	36
799	P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET PO INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767.	SITIVE 0.4	O
800	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA Aβ BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670.	0.4	1
801	P1â€001: CSF CHOLINE ACETYLTRANSFERASE SHOWS DIFFERENTIAL LEVELS AMONG HEALTHY CONTROLS AND PATIENTS WITH AD AND MCI. Alzheimer's and Dementia, 2018, 14, P261.	0.4	O
802	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 124.	3.0	273
803	Neurofilament Light in Serum and Cerebrospinal Fluid of Hip Fracture Patients with Delirium. Dementia and Geriatric Cognitive Disorders, 2018, 46, 346-357.	0.7	41
804	Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
805	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 2018, 14, 639-652.	4.9	434
806	Interlaboratory validation of cerebrospinal fluid αâ€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470.	1.2	7
807	Abnormal CSF amyloid- \hat{l}^2 42 and tau levels in hip fracture patients without dementia. PLoS ONE, 2018, 13, e0204695.	1.1	19
808	Heading in soccer increases serum neurofilament light protein and SCAT3 symptom metrics. BMJ Open Sport and Exercise Medicine, 2018, 4, e000433.	1.4	58
809	Effects of methylprednisolone on blood-brain barrier and cerebral inflammation in cardiac surgery—a randomized trial. Journal of Neuroinflammation, 2018, 15, 283.	3.1	38
810	Cerebrospinal fluid protein markers in PD patients after DBS-STN surgeryâ€"A retrospective analysis of patients that underwent surgery between 1993 and 2001. Clinical Neurology and Neurosurgery, 2018, 174, 174-179.	0.6	3

#	Article	IF	CITATIONS
811	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521.	0.4	163
812	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. Nutrition Research, 2018, 60, 13-25.	1.3	12
813	Early predictors of mortality in parkinsonism and Parkinson disease. Neurology, 2018, 91, e2045-e2056.	1.5	111
814	No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion. PLoS ONE, 2018, 13, e0206466.	1.1	31
815	DTâ€02â€01: APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1668.	0.4	0
816	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. Neurochemistry International, 2018, 121, 38-49.	1.9	20
817	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 87.	3.0	13
818	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of $\hat{A^2}$ species. NeuroImage: Clinical, 2018, 20, 603-610.	1.4	11
819	Therapeutic potential for peripheral clearance of misfolded brain proteins. Nature Reviews Neurology, 2018, 14, 637-638.	4.9	8
820	Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase. Molecular Neurodegeneration, 2018, 13, 47.	4.4	21
821	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177
822	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, S271-S279.	1.2	66
823	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals $\hat{A^2}$ Aggregation Dependent Anionic Lipid Accumulations and Metabolism. Analytical Chemistry, 2018, 90, 8130-8138.	3.2	39
824	Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review. European Neuropsychopharmacology, 2018, 28, 783-794.	0.3	18
825	A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older. Journal of Alzheimer's Disease, 2018, 63, 1325-1335.	1.2	6
826	Neurofilament relates to white matter microstructure in older adults. Neurobiology of Aging, 2018, 70, 233-241.	1.5	48
827	Trisomy of human chromosome 21 enhances amyloid- \hat{l}^2 deposition independently of an extra copy of <i> APP </i> Brain, 2018, 141, 2457-2474.	3.7	96
828	Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE E-4. SSM - Population Health, 2018, 5, 171-179.	1.3	24

#	Article	IF	CITATIONS
829	Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
830	Commutability of the certified reference materials for the standardization of \hat{l}^2 -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and \hat{l}^2 -amyloid 1-40 measurements. Clinical Chemistry and Laboratory Medicine, 2018, 56, 2058-2066.	1.4	27
831	Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Experimental Neurology, 2018, 307, 129-132.	2.0	51
832	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
833	No association of salivary total tau concentration with Alzheimer's disease. Neurobiology of Aging, 2018, 70, 125-127.	1.5	51
834	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
835	Biomarkers for Alzheimer's disease: current status and prospects for the future. Journal of Internal Medicine, 2018, 284, 643-663.	2.7	550
836	Levels of ADAM10 are reduced in Alzheimer's disease CSF. Journal of Neuroinflammation, 2018, 15, 213.	3.1	39
837	Association of cerebrospinal fluid αâ€synuclein with total and phosphoâ€tau ₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.4	45
838	Evidence for sex difference in the $\langle scp \rangle CSF \langle scp \rangle $ plasma albumin ratio in ~ 20000 patients and 335 healthy volunteers. Journal of Cellular and Molecular Medicine, 2018, 22, 5151-5154.	1.6	55
839	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 71.	3.0	216
840	Cerebrospinal fluid tau, $A\hat{l}^2$, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. Alzheimer's and Dementia, 2018, 14, 1159-1170.	0.4	96
841	Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Frontiers in Neurology, 2018, 9, 201.	1.1	31
842	The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain. Cell Death and Disease, 2018, 9, 775.	2.7	10
843	Effects of APOE $\hat{l}\mu4$ on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
844	Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study. PLoS ONE, 2018, 13, e0196025.	1.1	29
845	Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. Journal of Neuroinflammation, 2018, 15, 209.	3.1	94
846	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 62.	2.4	9

#	Article	IF	Citations
847	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 5.	3.0	94
848	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	3.0	79
849	Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurology, 2018, 75, 989.	4.5	223
850	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. Alzheimer's Research and Therapy, 2018, 10, 45.	3.0	11
851	Cerebrospinal fluid GAP-43 in early multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731879293.	0.5	8
852	Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. Journal of Proteome Research, 2018, 17, 4072-4084.	1.8	5
853	Midlife Stress in Relation to Late-Life Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: A 25-Year Follow-Up Study. Dementia and Geriatric Cognitive Disorders, 2018, 46, 90-99.	0.7	9
854	Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. Journal of NeuroVirology, 2018, 24, 695-701.	1.0	35
855	Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2018, 56, 98-101.	1.1	38
856	Update on biomarkers for amyloid pathology in Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 799-812.	0.6	59
857	Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease. PLoS ONE, 2018, 13, e0193492.	1.1	21
858	The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer's disease. PLoS ONE, 2018, 13, e0191240.	1.1	41
859	D08â \in Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtingtonâ \in TM s disease: a retrospective cohort analysis. , 2018, , .		0
860	HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain. Molecular Neurobiology, 2017, 54, 188-199.	1.9	13
861	CSF Aβ1–42 – an excellent but complicated Alzheimer's biomarker – a route to standardisation. Clinica Chimica Acta, 2017, 467, 27-33.	0.5	104
862	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 62-71.	1.4	81
863	Genome-wide association study identifies <i>MAPT</i> locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.5	33
864	Plasma concentrations of free amyloid \hat{l}^2 cannot predict the development of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 778-782.	0.4	70

#	Article	IF	Citations
865	Neurofilament Protein and Antineurofilament Antibodies Following Traumatic Brain Injury—Reply. JAMA Neurology, 2017, 74, 363.	4.5	4
866	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Translational Psychiatry, 2017, 7, e995-e995.	2.4	56
867	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
868	CSF YKLâ€40 and GAPâ€43 are related to suicidal ideation in older women. Acta Psychiatrica Scandinavica, 2017, 135, 351-357.	2.2	8
869	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	1.1	34
870	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.4	32
871	The effects of different familial Alzheimer's disease mutations on APP processing in vivo. Alzheimer's Research and Therapy, 2017, 9, 9.	3.0	32
872	Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing–remitting multiple sclerosis. European Journal of Neurology, 2017, 24, 703-712.	1.7	97
873	Astroglial activation and altered amyloid metabolism in human repetitive concussion. Neurology, 2017, 88, 1400-1407.	1.5	39
874	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
875	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. Journal of Neuroimmunology, 2017, 306, 25-30.	1.1	17
876	Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 391-402.	1.8	16
877	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 397-403.	1.1	58
878	Accuracy of cerebrospinal fluid ${\rm A\hat{l}^21\text{-}42}$ measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1545-1554.	1.4	14
879	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.5	369
880	The immune response of the human brain to abdominal surgery. Annals of Neurology, 2017, 81, 572-582.	2.8	87
881	Twoâ€level diagnostic classification using cerebrospinal fluid YKLâ€40 in Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 993-1003.	0.4	39
882	Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology, 2017, 88, 1788-1794.	1.5	280

#	Article	IF	Citations
883	Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 284-290.	1.8	23
884	Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain, Behavior, and Immunity, 2017, 65, 195-201.	2.0	69
885	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. Alzheimer's Research and Therapy, 2017, 9, 31.	3.0	36
886	A Season of American Football Is Not Associated with Changes in Plasma Tau. Journal of Neurotrauma, 2017, 34, 3295-3300.	1.7	14
887	Increased levels of ascorbic acid in the cerebrospinal fluid of cognitively intact elderly patients with major depression: a preliminary study. Scientific Reports, 2017, 7, 3485.	1.6	18
888	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	2.8	768
889	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. Methods in Molecular Biology, 2017, 1598, 101-115.	0.4	14
890	Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition. Journal of Alzheimer's Disease, 2017, 58, 829-840.	1.2	31
891	Serum concentrations of the axonal injury marker neurofilament light protein are not influenced by blood-brain barrier permeability. Brain Research, 2017, 1668, 12-19.	1.1	53
892	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. Neurochemistry International, 2017, 108, 355-360.	1.9	46
893	Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. Journal of Alzheimer's Disease, 2017, 58, 821-828.	1.2	12
894	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	1.6	28
895	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 1245-1254.	1.2	54
896	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Review of Molecular Diagnostics, 2017, 17, 761-770.	1.5	114
897	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	4.9	272
898	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
899	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. Expert Review of Neurotherapeutics, 2017, 17, 767-775.	1.4	4
900	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2017, 57, 387-393.	1.2	11

#	Article	IF	CITATIONS
901	The recency ratio is associated with reduced CSF glutamate in late-life depression. Neurobiology of Learning and Memory, 2017, 141, 14-18.	1.0	10
902	Alterations in the Balance of Amyloid-l̂² Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2017, 57, 1281-1291.	1.2	4
903	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2017, 74, 557.	4.5	664
904	Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease. Stem Cell Reports, 2017, 8, 870-882.	2.3	53
905	Clinical validity of cerebrospinal fluid $\hat{A^2}42$, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
906	Histology-Compatible MALDI Mass Spectrometry Based Imaging of Neuronal Lipids for Subsequent Immunofluorescent Staining. Analytical Chemistry, 2017, 89, 4685-4694.	3.2	60
907	The Effects of Gene Mutations onÂDefaultÂMode Network inÂFamilialÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 327-334.	1.2	8
908	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
909	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
910	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiology of Aging, 2017, 51, 104-112.	1.5	154
911	Expanding the cerebrospinal fluid endopeptidome. Proteomics, 2017, 17, 1600384.	1.3	28
912	Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2017, 8, 347-355.	1.7	66
913	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.5	204
914	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 2017, 89, 2230-2237.	1.5	307
915	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
916	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Proteomics - Clinical Applications, 2017, 11, 1700100.	0.8	28
917	Earliest accumulation of \hat{l}^2 -amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
918	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington's disease R6/2 mice. Scientific Reports, 2017, 7, 14114.	1.6	49

#	Article	IF	CITATIONS
919	Serum tau and neurological outcome in cardiac arrest. Annals of Neurology, 2017, 82, 665-675.	2.8	86
920	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. Expert Review of Proteomics, 2017, 14, 1007-1020.	1.3	21
921	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2017, 59, 1327-1334.	1.2	35
922	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Scientific Reports, 2017, 7, 13333.	1.6	45
923	Gut microbiome alterations in Alzheimer's disease. Scientific Reports, 2017, 7, 13537.	1.6	1,256
924	Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis. Journal of Neuroimmunology, 2017, 312, 15-18.	1.1	46
925	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Neurology and Therapy, 2017, 6, 15-24.	1.4	211
926	Alzheimer's disease markers in the aged sheep (Ovis aries). Neurobiology of Aging, 2017, 58, 112-119.	1.5	30
927	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 2017, 59, 1-9.	1.5	84
928	¹⁸ Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	3.3	156
929	Absolute Quantification of Aβ ₁₋₄₂ in CSF Using a Mass Spectrometric Reference Measurement Procedure. Journal of Visualized Experiments, 2017, , .	0.2	3
930	Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathologyâ€based cohort. European Journal of Neurology, 2017, 24, 1326.	1.7	71
931	[P3–273]: EFFECTS OF RISPERIDONE AND GALANTAMINE TREATMENT ON ALZHEIMER BIOMARKER LEVELS IN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2017, 13, P1047.	0.4	O
932	Low-dose \hat{l}^3 -secretase inhibition increases secretion of \hat{Al}^2 peptides and intracellular oligomeric \hat{Al}^2 . Molecular and Cellular Neurosciences, 2017, 85, 211-219.	1.0	6
933	[P2–141]: TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/Aβ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF ⟨i>APP⟨/i>. Alzheimer's and Dementia, 2017, 13, P661.	0.4	O
934	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2017, 7, e018177.	0.8	4
935	[P2–367]: CROSS‧ECTIONAL CORRELATION BETWEEN GTP1â€TAUâ€PET AND CSF TAU AS MEASURES OF TABURDEN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P766.	AU 0.4	O
936	Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 1017-1026.	1.2	24

#	Article	IF	CITATIONS
937	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023.	3.3	170
938	Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression. Journal of Neural Transmission, 2017, 124, 1641-1645.	1.4	3
939	[P4–182]: A NEUROBIOLOGICAL MODEL OF MEMORY IMPAIRMENT IN LATEâ€LIFE MAJOR DEPRESSIVE DISORU Alzheimer's and Dementia, 2017, 13, P1332.	DER. 0.4	1
940	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
941	Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology, 2017, 89, 445-453.	1.5	166
942	Ex vivo 180-labeling mass spectrometry identifies a peripheral amyloid \hat{l}^2 clearance pathway. Molecular Neurodegeneration, 2017, 12, 18.	4.4	17
943	Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. Journal of Neural Transmission, 2017, 124, 1135-1143.	1.4	19
944	The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). Virus Research, 2017, 227, 220-230.	1.1	24
945	Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease. JAMA Neurology, 2017, 74, 41.	4.5	147
946	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsingâ€remitting multiple sclerosis. Journal of Neurochemistry, 2017, 141, 296-304.	2.1	124
947	Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study. Journal of Neurotrauma, 2017, 34, 1124-1127.	1.7	104
948	CSF neurofilament light levels predict hippocampal atrophy in cognitively healthy older adults. Neurobiology of Aging, 2017, 49, 138-144.	1.5	60
949	Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumabâ€treated multiple sclerosis. European Journal of Neurology, 2017, 24, 112-121.	1.7	35
950	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. Alzheimer's and Dementia, 2017, 13, 59-71.	0.4	112
951	Cerebrospinal Fluid Stanniocalcin-1 as a Biomarker for Alzheimer's Disease and Other Neurodegenerative Disorders. NeuroMolecular Medicine, 2017, 19, 154-160.	1.8	18
952	Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals. Journal of NeuroVirology, 2017, 23, 106-112.	1.0	22
953	The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. American Journal of Geriatric Psychiatry, 2017, 25, 170-177.	0.6	13
954	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology, 2017, 74, 1492.	4.5	97

#	Article	IF	CITATIONS
955	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- \hat{l}^2 Concentration. Journal of Alzheimer's Disease, 2017, 56, 885-891.	1.2	6
956	[P1â€"221]: EXPRESSION AND SECRETION OF SYNAPTIC PROTEINS DURING DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO CORTICAL NEURONS. Alzheimer's and Dementia, 2017, 13, P328.	0.4	0
957	[P1–028]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13 P243.	,0.4	O
958	[P2–536]: THE PREVALENCE OF PRECLINICAL ALZHEIMER's DISEASE IN A POPULATION STUDY OF 70‥EAR Alzheimer's and Dementia, 2017, 13, P848.	OLDS.	2
959	[P3–084]: Nâ€TERMINAL FRAGMENT OF TAU: ASSAY DEVELOPMENT WITH INâ€HOUSE CLEAVAGEâ€SPECIFIC ANTIBODY. Alzheimer's and Dementia, 2017, 13, P964.	0.4	O
960	[P3–132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985.	0.4	0
961	[P3–171]: ACUTE, TRANSIENT INCREASE IN SECRETION OF NEURODEGENERATION BIOMARKERS AFTER IRRADIATION OF HUMAN CORTICAL NEURONS. Alzheimer's and Dementia, 2017, 13, P1000.	0.4	O
962	[P3–174]: EFFECT OF PHYSICAL EXERCISE ON MARKERS OF NEURONAL DYSFUNCTION IN CEREBROSPINAL FLUID IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1000.	0.4	0
963	[P3–198]: PREDICTION PERFORMANCE OF ALPHAâ€SYNUCLEIN PROTEIN IN PRECLINICAL SUBJECTIVE MEMOR' COMPLAINERS STRATIFIED BY AD BIOMARKERS: THE INSIGHTâ€PRE AD STUDY. Alzheimer's and Dementia, 2017, 13, P1011.	(0.4	O
964	[P3–423]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P1128.	0.4	0
965	[P3–425]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1130.	0.4	O
966	[P4–152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF βâ€AMYLOID (1–42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS. Alzheimer's and Dementia, 2017, 13, P1316.	0.4	1
967	[P4–163]: STATISTICAL ALGORITHMS FOR HARMONIZING BIOMARKER DISTRIBUTIONS ACROSS DIFFERENT COHORTS, SITES AND ASSAYS: APPLICATIONS TO CSF MEASUREMENTS. Alzheimer's and Dementia, 2017, 13, P1322.	0.4	O
968	[P1–150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN <i>IL1RAP</i> AND ALZHEIMER'sâ€RELATED CSFâ€BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P300.	0.4	0
969	[ICâ€Pâ€048]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P41.	0.4	O
970	[ICâ€Pâ€049]: REGIONAL DEFICIT IN SLEEPING BRAIN ACTIVITY ASSOCIATED WITH TAU AND AMYLOID PATHOLOGIN COGNITIVELY HEALTHY MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2017, 13, P41.	℃ 0.4	0
971	[P1–187]: NOVEL METHOD FOR OLIGOMERIC Aβ DETECTION REVEALS INTRACELLULAR ACCUMULATION OF AÎ UPON LOWâ€DOSE TREATMENT WITH A GAMMAâ€SECRETASE INHIBITOR. Alzheimer's and Dementia, 2017, 13, P314.)2 0.4	O
972	[P1â€"268]: ANALYSIS OF NEW POTENTIAL CSF BIOMARKERS FOR ALZHEIMER'S DISEASE BY PARALLEL REACTION MONITORING MASS SPECTROMETRY. Alzheimer's and Dementia, 2017, 13, P352.	0.4	0

#	Article	IF	Citations
973	[P1â€"281]: DIAGNOSTIC PERFORMANCE USING CSF YKLâ€40 IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P357.	⁻ 0.4	O
974	[P1â€"282]: DIAGNOSTIC ACCURACY OF CSF Aβ1â€"42, Pâ€TAU, Tâ€TAU, NEUROFILAMENT LIGHT CHAIN, NEUR YKLâ€40 COMBINED BIOMARKERS IN A MULTICENTER COHORT OF COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P358.	OGRANIN, 0.4	, O
975	[P1â€"287]: DIAGNOSTIC ACCURACY OF CSF NEUROFILAMENT LIGHT CHAIN PROTEIN IN THE UNBIASED BIOMARKERâ€GUIDED CLASSIFICATION SYSTEM FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13 P361.	,0.4	O
976	[P1–611]: LIFETIME PHYSICAL ACTIVITY IS ASSOCIATED WITH CSF AMYLOID IN COGNITIVELY ASYMPTOMATIC APOE É>4+ ADULTS. Alzheimer's and Dementia, 2017, 13, P530.	0.4	0
977	[P2–158]: IS THE PRESUBICULUM PROTECTED FROM NEURODEGENERATIVE CHANGES? A PATHOLOGICAL AND BIOCHEMICAL INVESTIGATION. Alzheimer's and Dementia, 2017, 13, P668.	0.4	O
978	[P2â€"208]: CSF AND PLASMA LEVELS OF INFLAMMATION DIFFERENTIALLY RELATE TO CNS MARKERS OF ALZHEIMER'S DISEASE PATHOLOGY AND NEURONAL DAMAGE. Alzheimer's and Dementia, 2017, 13, P689.	0.4	1
979	[P2â€"211]: AMYLOIDâ€Ĵ²42 (Aβ42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLA TAU IN AN AMYLOIDâ€POSITIVE VERSUS AMYLOIDâ€NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC ATâ€RIFOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.		O
980	[P2–241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.4	0
981	[P2–246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.4	O
982	[P2â€"260]: TWO‣EVEL DIAGNOSTIC CLASSIFICATION USING CEREBROSPINAL FLUID NEUROGRANIN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P712.	0.4	0
983	[P2â€"262]: ASSOCIATION OF PLASMA NEUROFILAMENT LIGHT CHAIN PROTEIN WITH BRAIN AMYLOID STATUS IN A PRECLINICAL COHORT OF SUBJECTIVE MEMORY COMPLAINERS: THE INSIGHTâ€PREAD STUDY. Alzheimer's and Dementia, 2017, 13, P713.	0.4	O
984	[F3–01–03]: THE PATHOGENIC BASIS OF THE ALZHEIMER CSF BIOMARKERS: WHAT DO WE KNOW TODAY?. Alzheimer's and Dementia, 2017, 13, P878.	0.4	0
985	[O4–02–01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON'S AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1228.	0.4	O
986	[O4–02–04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.4	0
987	[P4–392]: NOVEL ASSAYS TO MONITOR Aβ PEPTIDES GENERATED BY THE ASPARAGATE ENDOPEPTIDASE AFTE INHIBITION OF BACE. Alzheimer's and Dementia, 2017, 13, P1478.	Ro.4	O
988	[P4â€"470]: PRESYNAPTIC DEGRADATION IN ALZHEIMER's DISEASE MEASURED BY NOVEL GAPâ€43 ELISA IN CSF Alzheimer's and Dementia, 2017, 13, P1513.	0.4	0
989	[ICâ€Pâ€171]: MODERATE INTENSITY PHYSICAL ACTIVITY ASSOCIATES WITH CSF BIOMARKERS IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P128.	0.4	O
990	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. Journal of Visualized Experiments, 2017, , .	0.2	1

#	Article	IF	Citations
991	Factors Influencing Successful Lumbar Puncture in Alzheimer Research. Alzheimer Disease and Associated Disorders, 2017, 31, 287-294.	0.6	18
992	Mild traumatic brain injury is associated with increased levels of axonal injury biomarkers in blood. British Journal of Sports Medicine, 2017, 51, A6.3-A7.	3.1	1
993	[P3–075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
994	Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging. PLoS ONE, 2017, 12, e0173982.	1.1	104
995	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. Journal of Alzheimer's Disease, 2017, 60, 201-210.	1.2	11
996	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurology, 2017, 17, 170.	0.8	70
997	Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study. Journal of Neuroinflammation, 2017, 14, 193.	3.1	15
998	Preclinical effects of APOE $\hat{l}\mu 4$ on cerebrospinal fluid A $\hat{l}^2 42$ concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
999	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 95.	3.0	396
1000	Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity. Journal of Alzheimer's Disease, 2017, 60, 243-252.	1.2	15
1001	High-throughput analysis of sulfatides in cerebrospinal fluid using automated extraction and UPLC-MS/MS. Journal of Lipid Research, 2017, 58, 1482-1489.	2.0	14
1002	Tau or neurofilament lightâ€"Which is the more suitable biomarker for Huntington's disease?. PLoS ONE, 2017, 12, e0172762.	1,1	40
1003	Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment. PLoS ONE, 2017, 12, e0176760.	1.1	18
1004	Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimerâ∈™s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults. Journal of Alzheimer's Disease, 2016, 52, 1373-1383.	1.2	51
1005	A Genetic Variant of the Sortilin 1 Gene isÂAssociated with Reduced Risk ofÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 1353-1363.	1.2	28
1006	Association between APOE Genotype and Change in Physical Function in a Population-Based Swedish Cohort of Older Individuals Followed Over Four Years. Frontiers in Aging Neuroscience, 2016, 8, 225.	1.7	18
1007	Blood biomarkers indicate mild neuroaxonal injury and increased amyloid $\langle i \rangle \hat{l}^2 \langle i \rangle$ production after transient hypoxia during breath-hold diving. Brain Injury, 2016, 30, 1226-1230.	0.6	23
1008	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.5	1,216

#	Article	IF	Citations
1009	Update on fluid biomarkers for concussion. Concussion, 2016, 1, CNC12.	1.2	11
1010	<i>Apolipoprotein E</i> polymorphism in aneurysmal subarachnoid haemorrhage in West Sweden. Acta Neurologica Scandinavica, 2016, 133, 466-474.	1.0	12
1011	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimer's Research and Therapy, 2016, 8, 30.	3.0	110
1012	Cerebrospinal fluid levels of insulin, leptin, and agoutiâ€related protein in relation to BMI in pregnant women. Obesity, 2016, 24, 1299-1304.	1.5	10
1013	Cerebral white matter lesions $\hat{a} \in \hat{a}$ associations with \hat{A}^2 isoforms and amyloid PET. Scientific Reports, 2016, 6, 20709.	1.6	52
1014	Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 473-484.	1.2	93
1015	Associations between Performance onÂanÂAbbreviated CogState Battery, OtherÂMeasures of Cognitive Function, andÂBiomarkers in People at Risk forÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 1395-1408.	1.2	40
1016	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
1017	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
1018	Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	1.2	191
1019	Serum erythropoietin and outcome after ischaemic stroke: a prospective study. BMJ Open, 2016, 6, e009827.	0.8	9
1020	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Journal of Alzheimer's Disease, 2016, 55, 19-35.	1.2	35
1021	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in earlyâ€stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
1022	Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates. Journal of Alzheimer's Disease, 2016, 55, 303-313.	1.2	44
1023	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 41.	3.0	121
1024	Specific Triazine Herbicides Induce Amyloid-Î ² 42 Production. Journal of Alzheimer's Disease, 2016, 54, 1593-1605.	1.2	14
1025	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2016, 55, 1489-1496.	1,2	14
1026	Preclinical Amyloid- \hat{l}^2 and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	1.2	35

#	Article	IF	Citations
1027	D2â€Cerebrospinal fluid biomarkers in huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A34.2-A34.	0.9	0
1028	P3-129: Psychological Stress in Midlife Associated with Higher Levels of CSF T-TAU and AB40 in Late-Life: A 25-YEAR Longitudinal Population Study of Women. , 2016, 12, P869-P869.		0
1029	O1â€05â€01: Increased Amyloidogenic app Processing in Apoe E4â€Negative Individuals with Cerebral Bâ€Amyloidosis. Alzheimer's and Dementia, 2016, 12, P182.	0.4	0
1030	O5-01-02: Stress is Associated with Greater Insulin Resistance, Higher CSF Phosphorylated TAU, and Decreased Glucose Metabolism in the Medial Temporal Lobe in apoe î-4 Carriers., 2016, 12, P375-P376.		0
1031	P1â€172: Combined Added Value of Cerebrospinal Fluid Neurogranin and Neurofilament Light Chain Protein in the Diagnosis and Classification Of Prodromal and Alzheimer's Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468.	0.4	0
1032	ICâ€Pâ€050: MCI Status, Amyloid and TAU Biomarkers, and Composite Cognitive Impairment Scores are Associated with Cogstate Performance in The Wisconsin Registry For Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P41.	0.4	0
1033	P1â€322: Fourâ€Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and are Associated with CSF Biomarkers in Patients with MCI. Alzheimer's and Dementia, 2016, 12, P548.	0.4	0
1034	P1â€344: Poor Sleep Quality is Associated with CSF Markers of Amyloid Deposition in Cognitively Healthy Adults at Risk for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P561.	0.4	0
1035	P1â€410: Lifetime Recreational Physical Activity is Associated with CSF Amyloid in Cognitively Asymptomatic Adults. Alzheimer's and Dementia, 2016, 12, P591.	0.4	0
1036	P2â€151: Cerebrospinal Fluid Biomarker Profile of Amyloid, TAU, Synaptic, Microglial, and Lysosomal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloidâ€Pet Status. Alzheimer's and Dementia, 2016, 12, P672.	0.4	0
1037	P2â€152: Characterization of the Postsynaptic Protein Neurogranin in Different Brain Regions in Patients with Familial Alzheimer's Disease, Alzheimer's Disease, Pathological Aging And Healthy Controls. Alzheimer's and Dementia, 2016, 12, P672.	0.4	0
1038	P2â€142: Comparison of Tâ€Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P667.	0.4	0
1039	ICâ€Pâ€123: Four Dimensional Arterial Blood Flow Metrics in The Internal Carotid Artery Predict Cognitive Performance and Are Associated With CSF Biomarkers in Patients With MCI. Alzheimer's and Dementia, 2016, 12, P91.	0.4	0
1040	P2â€430: The Prevalence of Pathological CSF Abetaâ€42 and ITS Relation to Education in a Population Sample of Older People from Sweden. Alzheimer's and Dementia, 2016, 12, P810.	0.4	0
1041	P3-162: Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Chain Protein in the Classification of Prodromal and Alzheimer's Disease Dementia. , 2016, 12, P881-P881.		1
1042	P3-165: Plasma Biomarker Profile of Amyloid, TAU, and Neuronal Pathophysiology in Cognitively Normal Preclinical Individuals Stratified by Amyloid-Pet Status., 2016, 12, P882-P883.		0
1043	P3-193: Serum Neurofilament Light Protein Predicts Clinical Outcome in Traumatic Brain Injury. , 2016, 12, P896-P897.		0
1044	P4-114: Cerebrospinal Fluid Biomarkers of Neuronal Injury in Chronic Traumatic Brain Injury., 2016, 12, P1056-P1056.		0

#	Article	IF	CITATIONS
1045	FTS3â€01â€03: Biomarkers for Vascular Contributions to Dementia. Alzheimer's and Dementia, 2016, 12, P276.	0.4	0
1046	O1â€05â€06: Stability of Amyloidâ€Beta (1–42) in Fresh Versus Frozen Human Cerebrospinal Fluid Samples as Measured with the Elecsys [®] Bâ€Amyloid(1–42) Immunoassay. Alzheimer's and Dementia, 2016, 12, P185.	0.4	0
1047	O1â€10â€01: Gantenerumab Treatment Reduces Biomarkers of Neuronal and Synaptic Degeneration in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P198.	0.4	3
1048	O1â€11â€05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic. Alzheimer's and Dementia, 2016, 12, P203.	0.4	1
1049	O3-03-02: MCI STATUS, AMYLOID AND TAU BIOMARKERS, AND COMPOSITE COGNITIVE IMPAIRMENT SCORES ARE ASSOCIATED WITH COGSTATE PERFORMANCE IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. , 2016, 12, P285-P286.		0
1050	O3â€09â€01: Distinct Cognitive Trajectories in Late Middleâ€Age and their Associations with Brain Structure and Alzheimer's Disease Biomarkers: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia, 2016, 12, P306.	0.4	0
1051	O4â€10â€01: PLASMA NFL: A NEW BIOMARKER FOR DIFFERENTIAL DIAGNOSIS OF PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2016, 12, P357.	0.4	o
1052	P1-012: A Population-Based Study on the Relation Between Sleep Disturbance and Beta-Amyloid 42 in Cerebrospinal Fluid in 70-Year-Olds., 2016, 12, P404-P404.		0
1053	P1-028: Does Calcium Supplementation Increase the Risk of Dementia in Women With Cerebrovascular Disease? A Five Year Follow-Up of Older Swedish Women. , 2016, 12, P412-P412.		О
1054	P1â€171: Added Diagnostic Value of Cerebrospinal Fluid Neurogranin in the Classification of Prodromal and Alzheimer's Disease Dementia. Alzheimer's and Dementia, 2016, 12, P468.	0.4	0
1055	P1-177: How Accurate are Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease? A Systematic Review., 2016, 12, P471-P472.		O
1056	P1â€181: Stateâ€Dependent Alterations in CSF Aβ42 Levels in Cognitivelyâ€Intact Elderly With Late Life Major Depression. Alzheimer's and Dementia, 2016, 12, P473.	0.4	0
1057	P1â€197: Evalution TM , A Novel Multiplex Technology for Simultaneous Quantification of Inflammation Markers, βâ€Amyloid and TAU Proteins. Alzheimer's and Dementia, 2016, 12, P479.	0.4	0
1058	P1â€204: Neurogranin: a Specific Synaptic Biomarker for Amnestic Alzheimer's Disease?. Alzheimer's and Dementia, 2016, 12, P483.	0.4	0
1059	P4â€312: Progress on the Development of Certified Reference Materials for AB1â€42. Alzheimer's and Dementia, 2016, 12, P1153.	0.4	0
1060	P4â€313: Commutability of the Candidate Certified Reference Materials for the Standardization of Aβ1â€42 Measurements in Human Cerebrospinal Fluid. Alzheimer's and Dementia, 2016, 12, P1153.	0.4	0
1061	P4â€324: Plasma Neurofilament Light Concentration Predicts Longâ€Term Outcome an Acute Stroke. Alzheimer's and Dementia, 2016, 12, P1158.	0.4	0
1062	Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 873-886.	1.2	101

#	Article	IF	CITATIONS
1063	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	1.6	81
1064	Abnormality in glutamine–glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Translational Psychiatry, 2016, 6, e744-e744.	2.4	69
1065	Serum Neurofilament Light in American Football Athletes over the Course of a Season. Journal of Neurotrauma, 2016, 33, 1784-1789.	1.7	110
1066	Myo-inositol changes precede amyloid pathology and relate to <i>APOE</i> genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.5	66
1067	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurology, The, 2016, 15, 673-684.	4.9	1,413
1068	Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1655-1661.	1.4	517
1069	Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 112-117.	1.1	43
1070	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253.	0.8	64
1071	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- \hat{l}^2 in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	3.7	107
1072	Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurology, 2016, 73, 1308.	4.5	96
1073	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
1074	Cerebrospinal fluid-induced retardation of amyloid \hat{l}^2 aggregation correlates with Alzheimer's disease and the APOE $\hat{l}\mu 4$ allele. Brain Research, 2016, 1651, 11-16.	1.1	25
1075	Cerebrospinal fluid neurogranin and $\langle scp \rangle YKL \langle scp \rangle$ $\hat{a} \in 40$ as biomarkers of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 12-20.	1.7	137
1076	Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2016, 3, 216-225.	1.7	163
1077	<pre><scp>L</scp>ongitudinal <scp>M</scp>easurements of <scp>C</scp>erebrospinal <scp>F</scp>luid <scp>B</scp>iomarkers in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2016, 31, 898-905.</pre>	2.2	136
1078	Amyloid mis-metabolism in idiopathic normal pressure hydrocephalus. Fluids and Barriers of the CNS, 2016, 13, 13.	2.4	38
1079	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster. FEBS Journal, 2016, 283, 3508-3522.	2.2	15
1080	Reference measurement procedure for <scp>CSF</scp> amyloid beta (Aβ) _{1–42} and the <scp>CSF</scp> Aβ _{1–42} /Aβ _{1–40} ratio – a crossâ€validation study against amy <scp>PET</scp> . Journal of Neurochemistry, 2016, 139, 651-658.	lata	78

#	Article	IF	Citations
1081	Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology, 2016, 87, 1674-1680.	1.5	35
1082	Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. Journal of Neural Transmission, 2016, 123, 1443-1447.	1.4	39
1083	Plasma β-amyloid in Alzheimer's disease and vascular disease. Scientific Reports, 2016, 6, 26801.	1.6	442
1084	Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e271.	3.1	118
1085	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18
1086	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 98-102.	1.2	62
1087	Fluid biomarkers for mild traumatic brain injury and related conditions. Nature Reviews Neurology, 2016, 12, 563-574.	4.9	215
1088	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 2016, 87, 1329-1336.	1.5	354
1089	The clinical value of fluid biomarkers for dementia diagnosis – Authors' reply. Lancet Neurology, The, 2016, 15, 1204-1205.	4.9	7
1090	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P252.	0.4	0
1091	Traumatic brain injuries. Nature Reviews Disease Primers, 2016, 2, 16084.	18.1	380
1092	Increased amyloidogenic APP processing in APOE É-4-negative individuals with cerebral \hat{l}^2 -amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
1093	Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation. Scientific Reports, 2016, 6, 29200.	1.6	65
1094	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Scientific Reports, 2016, 6, 36791.	1.6	281
1095	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. Sleep, 2016, 39, 1253-1260.	0.6	44
1096	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 283-294.	0.6	33
1097	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 22.	3.0	39
1098	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A \hat{l}^2 42 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	0.6	140

#	Article	IF	CITATIONS
1099	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. Molecular Neurodegeneration, 2016, 11, 65.	4.4	16
1100	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseasesâ€"From pathophysiology to clinical practice. Movement Disorders, 2016, 31, 836-847.	2.2	54
1101	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict longâ€term outcome in patients with autoimmune encephalitis. European Journal of Neurology, 2016, 23, 796-806.	1.7	46
1102	<i>APOE</i> Îμ4 carriers may undergo synaptic damage conferring risk ofÂAlzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1159-1166.	0.4	29
1103	Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife. Brain, 2016, 139, 2261-2274.	3.7	41
1104	Cerebrospinal fluid ratios with Aβ ₄₂ predict preclinical brain βâ€amyloid accumulation. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 27-38.	1,2	44
1105	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. Clinical Proteomics, 2016, 13, 4.	1.1	22
1106	Low Circulating Acute Brain-Derived Neurotrophic Factor Levels Are Associated With Poor Long-Term Functional Outcome After Ischemic Stroke. Stroke, 2016, 47, 1943-1945.	1.0	98
1107	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Molecular Neurodegeneration, 2016, 11, 3.	4.4	236
1108	Serum Tau Fragments Predict Return to Play in Concussed Professional Ice Hockey Players. Journal of Neurotrauma, 2016, 33, 1995-1999.	1.7	71
1109	Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology, 2016, 86, 829-835.	1.5	170
1110	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Multiple Sclerosis Journal, 2016, 22, 1587-1595.	1.4	73
1111	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
1112	$\langle scp \rangle CSF \langle scp \rangle A \langle i \rangle \hat{l}^2 \langle i \rangle 42 A \langle i \rangle \hat{l}^2 \langle i \rangle 40$ and $A \langle i \rangle \hat{l}^2 \langle i \rangle 42 A \langle i \rangle \hat{l}^2 \langle i \rangle 38$ ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
1113	<i>CACNA1C</i> polymorphism and altered phosphorylation of tau in bipolar disorder. British Journal of Psychiatry, 2016, 208, 195-196.	1.7	19
1114	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	6.3	2,430
1115	Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1826-34.	3.3	492
1116	A single dose of the \hat{l}^3 -secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans. Alzheimer's Research and Therapy, 2016, 8, 11.	3.0	15

#	Article	IF	CITATIONS
1117	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 292, 52-57.	1.1	64
1118	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. Neurochemistry International, 2016, 93, 1-5.	1.9	17
1119	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine, 2016, 3, 135-140.	2.7	360
1120	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation ofÂβâ€amyloid (1–42) in human cerebrospinal fluid. Alzheimer's and Dementia, 2016, 12, 517-526	0.4	254
1121	Round robin test on quantification of amyloidâ $\in \hat{l}^2$ 1â \in 42 in cerebrospinal fluid by mass spectrometry. Alzheimer's and Dementia, 2016, 12, 55-59.	0.4	46
1122	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	4.5	354
1123	Assessing the commutability of reference material formats for the harmonization of amyloid- \hat{l}^2 measurements. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1177-1191.	1.4	49
1124	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
1125	C3 deficiency ameliorates the negative effects of irradiation of the young brain on hippocampal development and learning. Oncotarget, 2016, 7, 19382-19394.	0.8	21
1126	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. Journal of the International Neuropsychological Society, 2015, 21, 841-850.	1.2	49
1127	P4-004: Cardiorespiratory capacity modifies the association between a polygenic risk score and CSF biomarkers in preclinical Alzheimer's disease., 2015, 11, P766-P766.		1
1128	P2-063: $A\hat{1}^2$ 40 and $A\hat{1}^2$ 42 levels in plasma: Comparison of enzyme-linked immunosorbent assay (ELISA) with multiplex technology. , 2015, 11, P507-P507.		0
1129	Intracranial arterial fourâ€dimensional flow is associated with metrics ofÂbrain health and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 420-428.	1.2	28
1130	P1-316: The role of lysozyme in Alzheimer's disease. , 2015, 11, P477-P478.		6
1131	P3-103: Assessing the significance of insulin resistance on cerebrospinal fluid Alzheimer's disease biomarkers and memory function in people at risk for Alzheimer's disease: Findings from the wisconsin adrc impact cohort., 2015, 11, P659-P660.		0
1132	P1-069: Moderate-to-high intensity physical training does not alter cerebrospinal amyloid- \hat{l}^2 1-42 levels in patients with Alzheimer's disease., 2015, 11, P364-P365.		0
1133	P1-204: Insulin resistance is associated with altered microstructure in the medial temporal lobe and fornix of cognitively healthy ApoE $\hat{l}\mu 4$ carriers. , 2015, 11, P427-P428.		O
1134	Alzheimer's disease. Nature Reviews Disease Primers, 2015, 1, 15056.	18.1	1,210

#	Article	IF	Citations
1135	Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function. Journal of Alzheimer's Disease, 2015, 44, 1313-1322.	1.2	26
1136	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 49, 93-100.	1.2	35
1137	Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. Journal of Alzheimer's Disease, 2015, 49, 733-741.	1.2	18
1138	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	1.2	34
1139	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels inÂPatients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	1.2	28
1140	Biomarkers in Sporadic and Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 291-317.	1.2	75
1141	37 Years of Body Mass Index and Dementia: Effect Modification by the APOE Genotype: Observations from the Prospective Population Study of Women in Gothenburg, Sweden. Journal of Alzheimer's Disease, 2015, 48, 1119-1127.	1.2	27
1142	Increased Cerebrospinal Fluid Level ofÂlnsulin-like Growth Factor-II in Male Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 637-646.	1.2	40
1143	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9â€year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411.	1.2	26
1144	P4-038: Factors influencing lumbar puncture participation in Alzheimer's research., 2015, 11, P780-P780.		3
1145	P1-099: White matter lesions but not lacunes are associated with the CSF levels of $A\hat{l}^2$ 38 and $A\hat{l}^2$ 40, and to a lesser degree with CSF $A\hat{l}^2$ 42., 2015, 11, P376-P377.		0
1146	P2-062: Are cerebrospinal fluid levels of neurogranin associated with hippocampal atrophy and brain white matter volume decrease?., 2015, 11, P506-P507.		0
1147	APLP1 as a cerebrospinal fluid biomarker for \hat{l}^3 -secretase modulator treatment. Alzheimer's Research and Therapy, 2015, 7, 77.	3.0	9
1148	Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with AÎ ² 42 and influence of disease on the totalâ€AÎ ² 42/AÎ ² 40 ratio. Journal of Neurochemistry, 2015, 135, 1049-1058.	2.1	18
1149	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 74.	3.0	109
1150	Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOE É>4 Carriers. Journal of Alzheimer's Disease, 2015, 46, 525-533.	1.2	65
1151	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. Journal of Alzheimer's Disease, 2015, 47, 661-667.	1.2	14
1152	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348

#	Article	IF	CITATIONS
1153	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	1.1	36
1154	The past and the future of Alzheimer's disease CSF biomarkersâ€"a journey toward validated biochemical tests covering the whole spectrum of molecular events. Frontiers in Neuroscience, 2015, 9, 345.	1.4	66
1155	Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls. PLoS ONE, 2015, 10, e0127100.	1.1	38
1156	Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 250-258.	1.4	75
1157	First effects of rising amyloid- \hat{l}^2 in transgenic mouse brain: synaptic transmission and gene expression. Brain, 2015, 138, 1992-2004.	3.7	67
1158	Rarity of the Alzheimer Disease–Protective <i>APP</i> A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
1159	Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.4	205
1160	CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. European Neuropsychopharmacology, 2015, 25, 1091-1098.	0.3	47
1161	P4-066: The relationship between intracranial vascular health and metrics of Alzheimer's disease. , 2015, 11, P793-P794.		O
1162	P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?., 2015, 11, P340-P340.		0
1163	P1-110: Predictors of cognitive decline in elderly depressives. , 2015, 11, P381-P382.		O
1164	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions., 2015, 11, P384-P384.		1
1165	P1-116: Correlation of the modified innotest \hat{l}^2 -amyloid 1-42 with a lc-ms/ms candidate reference method. , 2015, 11, P385-P385.		1
1166	P2-074: Differences in the TREM2 levels in the CSF of Alzheimer's disease cases and controls. , 2015, 11, P511-P511.		0
1167	P4-036: CSF Alzheimer's disease-related biomarkers are higher in subjects with periodontal disease. , 2015, 11, P779-P779.		O
1168	P1-033: A candidate reference method for analysis of amyloid beta 1-42 (Aß1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer. , 2015, 11, P349-P349.		0
1169	Independent information from cerebrospinal fluid amyloid- \hat{l}^2 and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
1170	Alzheimer's disease â€" Recent biomarker developments in relation to updated diagnostic criteria. Clinica Chimica Acta, 2015, 449, 3-8.	0.5	25

#	Article	IF	Citations
1171	White matter changes in familial Alzheimer's disease. Journal of Internal Medicine, 2015, 278, 211-218.	2.7	30
1172	Fluid markers of traumatic brain injury. Molecular and Cellular Neurosciences, 2015, 66, 99-102.	1.0	43
1173	A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals. Neuropsychologia, 2015, 69, 1-8.	0.7	25
1174	Explorative and targeted neuroproteomics in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 769-778.	1.1	41
1175	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	0.9	196
1176	The Distribution of Apolipoprotein E Genotype Over The Adult Lifespan and in Relation to Country of Birth. American Journal of Epidemiology, 2015, 181, 214-217.	1.6	27
1177	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.4	50
1178	Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. Nature Medicine, 2015, 21, 217-219.	15.2	68
1179	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254
1180	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's and Dementia, 2015, 11, 772-791.	0.4	79
1181	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
1182	Cerebrospinal fluid tau and amyloid- \hat{l}^2 < sub>1-42 < /sub>in patients with dementia. Brain, 2015, 138, 2716-2731.	3.7	152
1183	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
1184	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. Clinica Chimica Acta, 2015, 449, 9-15.	0.5	66
1185	Benchmarking biomarkerâ€based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer's and Dementia, 2015, 11, 1470-1479.	0.4	17
1186	APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons. Cell Reports, 2015, 11, 689-696.	2.9	158
1187	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
1188	Laboratory Testing for Lyme Neuroborreliosis. JAMA Neurology, 2015, 72, 125.	4.5	1

#	Article	IF	CITATIONS
1189	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A largeâ€scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104
1190	Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 550-561.	1.4	126
1191	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
1192	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39
1193	Protective properties of lysozyme on \hat{l}^2 -amyloid pathology: implications for Alzheimer disease. Neurobiology of Disease, 2015, 83, 122-133.	2.1	58
1194	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2015, 85, 1834-1842.	1.5	109
1195	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurology, 2015, 72, 1175.	4. 5	148
1196	The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 81-86.	1.2	7
1197	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimer's Research and Therapy, 2015, 7, 40.	3.0	104
1198	Câ€terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1461-1469.	0.4	117
1199	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.5	288
1200	Neurogranin Levels in Cerebrospinal Fluid. JAMA Neurology, 2015, 72, 1237.	4.5	19
1201	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain, 2015, 138, 3373-3385.	3.7	200
1202	Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease. Neuroscience Letters, 2015, 609, 58-62.	1.0	20
1203	A 9-Year Prospective Population-Based Study on the Association Between the APOE*E4 Allele and Late-Life Depression in Sweden. Biological Psychiatry, 2015, 78, 730-736.	0.7	70
1204	Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain, Behavior, and Immunity, 2015, 43, 198-204.	2.0	51
1205	Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms. Journal of Neurotrauma, 2015, 32, 1294-1300.	1.7	99
1206	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 455-461.	0.4	9

#	Article	IF	CITATIONS
1207	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 58-69.	0.4	352
1208	ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-8.	1.5	35
1209	AMYLOID AND TAU BIOMARKERS IN CSF. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-5.	1.5	5
1210	Cerebrospinal fluid markers of central nervous system injury in decompression illness - a case-controlled pilot study. Diving and Hyperbaric Medicine, 2015, 45, 240-3.	0.2	4
1211	Neurological Assessment and Its Relationship to CSF Biomarkers in Amateur Boxers. PLoS ONE, 2014, 9, e99870.	1.1	30
1212	Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 385-394.	0.6	33
1213	Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach. Molecular and Cellular Proteomics, 2014, 13, 2584-2592.	2.5	26
1214	\hat{l}^2 -site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces A \hat{l}^2 5-X peptides through alternative amyloid precursor protein cleavage. Alzheimer's Research and Therapy, 2014, 6, 75.	3.0	31
1215	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Translational Psychiatry, 2014, 4, e419-e419.	2.4	39
1216	Comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice― Science Translational Medicine, 2014, 6, 268le5.	5.8	8
1217	Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 297-304.	0.6	82
1218	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	1.7	96
1219	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Molecular Neurodegeneration, 2014, 9, 53.	4.4	216
1220	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 549-560.	1.5	99
1221	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid Î ² -Amyloid 42. JAMA Neurology, 2014, 71, 1282.	4.5	300
1222	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
1223	Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 476.	4.5	164
1224	Tau, S-100 Calcium-Binding Protein B, and Neuron-Specific Enolase as Biomarkers of Concussion—Reply. JAMA Neurology, 2014, 71, 926.	4.5	8

#	Article	IF	CITATIONS
1225	Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 877-886.	1.2	26
1226	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology, 2014, 83, 1945-1953.	1.5	213
1227	Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey Players. JAMA Neurology, 2014, 71, 684.	4.5	336
1228	CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. Journal of Neuroimmunology, 2014, 269, 87-89.	1.1	51
1229	Neurochemical Evidence of Potential Neurotoxicity After Prophylactic Cranial Irradiation. International Journal of Radiation Oncology Biology Physics, 2014, 89, 607-614.	0.4	16
1230	The amyloid-β degradation pattern in plasmaâ€"A possible tool for clinical trials in Alzheimer's disease. Neuroscience Letters, 2014, 573, 7-12.	1.0	62
1231	The future of bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 115-131.	0.4	250
1232	Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer's Disease. Neuropsychopharmacology, 2014, 39, 189-201.	2.8	66
1233	Cerebrospinal fluid biomarkers in cardiac arrest survivors. Resuscitation, 2014, 85, 227-232.	1.3	25
1234	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
1235	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 322-333.	13.9	1,613
1236	CSF A \hat{l}^2 1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease., 2014, 10, 381-392.		64
1237	Elevated Concentrations of Neurofilament Light Chain in the Cerebrospinal Fluid of Bipolar Disorder Patients. Neuropsychopharmacology, 2014, 39, 2349-2356.	2.8	68
1238	CSF AÎ ² ₄₂ predicts early-onset dementia in Parkinson disease. Neurology, 2014, 82, 1784-1790.	1.5	135
1239	Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid. Clinical Chemistry, 2014, 60, 987-994.	1.5	132
1240	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
1241	Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E â^4 status and cerebrospinal fluid amyloid-β42 levels. Alzheimer's Research and Therapy, 2014, 6, 20.	3.0	48
1242	Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down's Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28

#	Article	IF	CITATIONS
1243	The cerebrospinal fluid "Alzheimer profileâ€. Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
1244	Automated cerebrospinal fluid cell count â€" New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry, 2014, 47, 25-30.	0.8	22
1245	The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Neurobiology of Aging, 2014, 35, 1318-1324.	1.5	109
1246	Imatinib treatment and A \hat{l}^2 42 in humans. Alzheimer's and Dementia, 2014, 10, S374-80.	0.4	15
1247	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. Biochemical Pharmacology, 2014, 88, 426-449.	2.0	105
1248	Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research and Therapy, 2014, 6, 25.	3.0	169
1249	Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain, Behavior, and Immunity, 2014, 41, 55-58.	2.0	75
1250	Blood–cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Research, 2014, 217, 143-146.	1.7	36
1251	Cerebrospinal fluid sphingolipids, \hat{l}^2 -amyloid, and tau in adults at risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2486-2494.	1.5	57
1252	CSF biomarkers for Alzheimer's pathology and the effect size of APOE É>4. Molecular Psychiatry, 2014, 19, 148-149.	4.1	30
1253	Brain Changes in Alzheimer's Disease Patients with Implanted Encapsulated Cells Releasing Nerve Growth Factor. Journal of Alzheimer's Disease, 2014, 43, 1059-1072.	1.2	71
1254	Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 335-343.	0.6	32
1255	Neuronal and Glia-Related Biomarkers in Cerebrospinal Fluid of Patients with Acute Ischemic Stroke. Journal of Central Nervous System Disease, 2014, 6, JCNSD.S13821.	0.7	82
1256	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	1.2	53
1257	Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1393-1402.	1.2	26
1258	P4-049: IMPACT OF READY TO USE CALIBRATORS AND THE USE OF UNIFIED STANDARD OPERATING PROCEDURES ON THE VARIABILITY IN ASSAY PERFORMANCE. , 2014, 10, P800-P800.		0
1259	P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE. , 2014, 10, P511-P511.		O
1260	P3-103: INCREASED LEVELS OF CEREBROSPINAL FLUID FATTY ACID BINDING PROTEIN 3 ARE RELATED TO DEMENTIA DEVELOPMENT IN A POPULATION-BASED SAMPLE OF ELDERLY WOMEN FOLLOWED FOR 8 YEARS. , 2014, 10, P666-P666.		o

#	Article	IF	CITATIONS
1261	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. journal of prevention of Alzheimer's disease, The, 2014, 1, 1-22.	1.5	48
1262	Plasma tau levels in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 9.	3.0	328
1263	Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application. Alzheimer's Research and Therapy, 2013, 5, 2.	3.0	16
1264	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
1265	Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study. Resuscitation, 2013, 84, 351-356.	1.3	199
1266	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
1267	The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 369-376.	1.1	53
1268	Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. Journal of Neurology, 2013, 260, 620-626.	1.8	87
1269	A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of AÎ ² 38, AÎ ² 40, and AÎ ² 42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2013, 33, 1021-1032.	1.2	100
1270	Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Injury, 2013, 27, 425-433.	0.6	127
1271	Idiopathic normal-pressure hydrocephalus. Neurology, 2013, 80, 1385-1392.	1.5	140
1272	Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer's Disease. PLoS ONE, 2013, 8, e76523.	1.1	173
1273	Cerebrospinal Fluid Levels ofl ² -Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Archives of General Psychiatry, 2012, 69, 98.	13.8	554
1274	The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron, 2012, 76, 886-899.	3.8	555
1275	Fluid Biomarkers in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006221-a006221.	2.9	159
1276	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.9	407
1277	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomarkers in Medicine, 2012, 6, 409-417.	0.6	76
1278	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS ONE, 2012, 7, e38639.	1.1	73

#	Article	IF	CITATIONS
1279	An online nanoâ€LCâ€ESlâ€FTICRâ€MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 2012, 47, 591-603.	0.7	78
1280	SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration. Journal of Proteomics, 2011, 75, 425-434.	1.2	56
1281	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
1282	Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid \hat{l}^2 Levels in Humans. PLoS ONE, 2011, 6, e28263.	1.1	149
1283	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68
1284	No neurochemical evidence of brain injury after blast overpressure by repeated explosions or firing heavy weapons. Acta Neurologica Scandinavica, 2011, 123, 245-251.	1.0	28
1285	Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. NeuroMolecular Medicine, 2011, 13, 151-159.	1.8	104
1286	Paving the way for Alzheimer disease drug development. Nature Reviews Neurology, 2011, 7, 65-66.	4.9	7
1287	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. Journal of Alzheimer's Disease, 2010, 21, 1119-1128.	1.2	110
1288	Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathologica, 2010, 120, 185-193.	3.9	268
1289	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Research, 2010, 1362, 13-22.	1.1	180
1290	Cerebrospinal fluid biomarkers of white matter lesions – crossâ€sectional results from the LADIS study. European Journal of Neurology, 2010, 17, 377-382.	1.7	100
1291	Biomarkers in Alzheimer's disease drug development. Nature Medicine, 2010, 16, 1218-1222.	15.2	118
1292	Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid. International Journal of Alzheimer's Disease, 2010, 2010, 1-11.	1.1	161
1293	Evaluation of plasma \hat{A}^240 and \hat{A}^242 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	1.5	242
1294	The ACE Insertion Deletion polymorphism relates to dementia by metabolic phenotype, APOEÉ, 4, and age of dementia onset. Neurobiology of Aging, 2010, 31, 910-916.	1.5	21
1295	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 131-144.	4.9	1,598
1296	CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology, 2010, 74, 1531-1537.	1.5	182

#	Article	IF	CITATIONS
1297	Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?. Alzheimer's Research and Therapy, 2010, 2, 8.	3.0	19
1298	Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the <i>APOE </i> ε <i>4</i> /ε <i>4</i> Genotype. Dementia and Geriatric Cognitive Disorders, 2009, 27, 458-464.	0.7	119
1299	Low frequency of post-lumbar puncture headache in demented patients. Acta Neurologica Scandinavica, 2009, 88, 221-223.	1.0	74
1300	Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585.	1.2	60
1301	Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 2009, 65, 403-413.	2.8	1,803
1302	Use of CSF biomarkers in Alzheimer's disease clinical trials. Journal of Nutrition, Health and Aging, 2009, 13, 358-361.	1.5	15
1303	Evolution of A $\hat{1}^2$ 42 and A $\hat{1}^2$ 40 levels and A $\hat{1}^2$ 42/A $\hat{1}^2$ 40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. Journal of Nutrition, Health and Aging, 2009, 13, 205-208.	1.5	52
1304	The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiology of Aging, 2009, 30, 672-681.	1.5	80
1305	Transient Inflammation in Neurogenic Regions after Irradiation of the Developing Brain. Radiation Research, 2009, 171, 66-76.	0.7	77
1306	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
1307	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627.	4.9	542
1308	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Archives of Neurology, 2008, 65, 1102-7.	4.9	193
1309	What is the future for CSF biomarkers in the prediction of cognitive decline and Alzheimer's disease?. Aging Health, 2008, 4, 213-215.	0.3	0
1310	Prediction of Alzheimer's Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 316-320.	0.7	248
1311	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2007, 24, 118-124.	0.7	148
1312	Characterization of Amyloid \hat{l}^2 Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry. Journal of Proteome Research, 2007, 6, 4433-4439.	1.8	135
1313	Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neuroscience Letters, 2007, 419, 18-22.	1.0	169
1314	Cystatin C in cerebrospinal fluid and multiple sclerosis. Annals of Neurology, 2007, 62, 193-196.	2.8	31

#	Article	IF	CITATIONS
1315	Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine, 2007, 13, 1359-1362.	15.2	969
1316	Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of <i>SOD1</i> genotype. European Journal of Neurology, 2007, 14, 1329-1333.	1.7	118
1317	Alzheimer's disease. Lancet, The, 2006, 368, 387-403.	6.3	3,074
1318	Determination of \hat{l}^2 -Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. Journal of Proteome Research, 2006, 5, 1010-1016.	1.8	187
1319	Neurochemical aftermath of amateur boxing. Scandinavian Journal of Medicine and Science in Sports, 2006, 16, 470-470.	1.3	2
1320	Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid- \hat{l}^2 1-42 and plasma apolipoprotein levels. Journal of Human Genetics, 2006, 51, 171-179.	1.1	10
1321	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, The, 2006, 5, 228-234.	4.9	1,494
1322	Cerebrospinal fluid Â-amyloid 1-42 concentration may predict cognitive decline in older women. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 461-464.	0.9	189
1323	Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology, 2006, 67, 1600-1604.	1.5	279
1324	Neurochemical Aftermath of Amateur Boxing. Archives of Neurology, 2006, 63, 1277.	4.9	310
1325	Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine, 2006, 44, 1472-80.	1.4	145
1326	The transcobalamin 776C>G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease. International Psychogeriatrics, 2005, 17, 329-331.	0.6	3
1327	Simultaneous Measurement of \hat{l}^2 -Amyloid($1\hat{a}\in$ "42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology. Clinical Chemistry, 2005, 51, 336-345.	1.5	400
1328	CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Review of Molecular Diagnostics, 2005, 5, 661-672.	1.5	122
1329	Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. International Journal of Molecular Medicine, 2005, 16, 1147-9.	1.8	44
1330	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease. Archives of General Psychiatry, 2004, 61, 95.	13.8	390
1331	CSF biomarkers for mild cognitive impairment. Journal of Internal Medicine, 2004, 256, 224-234.	2.7	138
1332	Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine, 2004, 256, 240-246.	2.7	4,039

#	Article	IF	Citations
1333	Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx, 2004, 1, 213-225.	6.0	418
1334	Cerebrospinal fluid protein biomarkers for Alzheimer's disease. Neurotherapeutics, 2004, 1, 213-225.	2.1	0
1335	CSF markers for incipient Alzheimer's disease. Lancet Neurology, The, 2003, 2, 605-613.	4.9	1,156
1336	Lipid analyses of human brain rafts. Journal of Neurochemistry, 2003, 85, 34-34.	2.1	3
1337	CSF A \hat{l}^2 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 2003, 60, 652-656.	1.5	532
1338	CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Research Bulletin, 2003, 61, 235-242.	1.4	68
1339	An 18-Year Follow-up of Overweight and Risk of Alzheimer Disease. Archives of Internal Medicine, 2003, 163, 1524.	4.3	671
1340	Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds. Dementia and Geriatric Cognitive Disorders, 2003, 15, 169-176.	0.7	170
1341	Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. Archives of Neurology, 2002, 59, 1267.	4.9	256
1342	CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology, 2002, 59, 627-629.	1.5	227
1343	Decreased CSF-β-Amyloid 42 in Alzheimer's Disease and Amyotrophic Lateral Sclerosis May Reflect Mismetabolism of β-Amyloid Induced by Disparate Mechanisms. Dementia and Geriatric Cognitive Disorders, 2002, 13, 112-118.	0.7	125
1344	Reply to †MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis'. European Journal of Human Genetics, 2002, 10, 579-582.	1.4	8
1345	Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neuroscience Letters, 2001, 297, 187-190.	1.0	401
1346	The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer's Disease, Reflecting a Common Pathophysiological Process. Dementia and Geriatric Cognitive Disorders, 2001, 12, 257-264.	0.7	102
1347	Neurofilament protein in cerebrospinal fluid: A marker of white matter changes. Journal of Neuroscience Research, 2001, 66, 510-516.	1.3	175
1348	Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis, 2001, 22, 1834-1837.	1.3	34
1349	Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electophoresis approach prior to mass spectrometry. Proteomics, 2001, 1, 444-452.	1.3	112
1350	CSF Total tau, $\hat{Al^2}42$ and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease. Molecular Neurobiology, 2001, 24, 087-098.	1.9	232

#	Article	IF	CITATIONS
1351	Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. European Journal of Human Genetics, 2001, 9, 437-444.	1.4	142
1352	Evaluation of CSF-tau and CSF- \hat{A}^2 42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice. Archives of Neurology, 2001, 58, 373-9.	4.9	487
1353	Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochemical Research, 2000, 25, 511-517.	1.6	80
1354	No association between the $\hat{1}\pm2$ -macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. Journal of Neural Transmission, 2000, 107, 1065-1079.	1.4	101
1355	Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. Journal of Neural Transmission, 2000, 107, 1085-1097.	1.4	25
1356	CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. Journal of Neural Transmission, 2000, 107, 563-579.	1.4	227
1357	Cerebrospinal Fluid Markers for Alzheimer's Disease Evaluated after Acute Ischemic Stroke. Journal of Alzheimer's Disease, 2000, 2, 199-206.	1.2	183
1358	Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neuroscience Letters, 2000, 285, 49-52.	1.0	452
1359	Standardization of measurement of \hat{l}^2 -amyloid ₍₁₋₄₂₎ in cerebrospinal fluid and plasma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 245-258.	1.4	286
1360	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2000, 12, 11-20.	0.7	0
1361	Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease. Archives of Neurology, 1999, 56, 673.	4.9	594
1362	Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. Journal of Clinical Immunology, 1999, 19, 223-230.	2.0	300
1363	The Growth-Associated Protein GAP-43 Is Increased in the Hippocampus and in the Gyrus Cinguli in Schizophrenia. Journal of Molecular Neuroscience, 1999, 13, 101-110.	1.1	49
1364	Identification of proteins in a human pleural exudate using two-dimensional preparative liquid-phase electrophoresis and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis, 1999, 20, 860-865.	1.3	49
1365	Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis, 1999, 20, 431-437.	1.3	89
1366	Removal of sodium dodecyl sulfate from protein samples prior to matrix-assisted laser desorption/ionization mass spectrometry. Rapid Communications in Mass Spectrometry, 1999, 13, 344-349.	0.7	91
1367	Analysis of intact proteins from cerebrospinal fluid by matrix-assisted laser desorption/ionization mass spectrometry after two-dimensional liquid-phase electrophoresis., 1999, 13, 2450-2455.		19
1368	Cerebrospinal fluid tau and \hat{Al}^2 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neuroscience Letters, 1999, 273, 5-8.	1.0	239

#	Article	IF	Citations
1369	Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 1998, 19, 379-384.	1.5	80
1370	Neurochemical Dissection of Synaptic Pathology in Alzheimer's Disease. International Psychogeriatrics, 1998, 10, 11-23.	0.6	161
1371	Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. Journal of Neural Transmission Supplementum, 1998, 53, 223-235.	0.5	28
1372	Decreased Lumbar Cerebrospinal Fluid Levels of Monoamine Metabolites in Vascular Dementia. International Psychogeriatrics, 1996, 8, 425-436.	0.6	21
1373	Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. Journal of Neural Transmission, 1996, 103, 603-618.	1.4	172
1374	Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid. Molecular and Chemical Neuropathology, 1996, 27, 195-210.	1.0	85
1375	The neurochemistry of Alzheimer's disease. Acta Neurologica Scandinavica, 1996, 94, 77-86.	1.0	14
1376	Stepwise Comparative Status Analysis (STEP): A Tool for Identification of Regional Brain Syndromes in Dementia. Journal of Geriatric Psychiatry and Neurology, 1996, 9, 185-199.	1.2	84
1377	tau protein in cerebrospinal fluid. Molecular and Chemical Neuropathology, 1995, 26, 231-245.	1.0	704
1378	Detection of cerebrospinal fluid leakage by isoelectric focusing on polyacrylamide gels with silver staining using the PhastSystem?. Acta Neurochirurgica, 1995, 136, 135-139.	0.9	16
1379	Chromogranin A in Cerebrospinal Fluid: A Biochemical Marker for Synaptic Degeneration in Alzheimer's Disease?. Dementia and Geriatric Cognitive Disorders, 1995, 6, 306-311.	0.7	24
1380	Cerebrospinal Fluid â€~Neuronal Thread Protein' Comes from Serum by Passage over the Blood-Brain Barrier. Experimental Neurology, 1995, 4, 187-193.	1.7	16
1381	Cerebrospinal Fluid Biochemical Markers in Alzheimer's Disease. , 1995, , 13-24.		0
1382	Neuron specific enolase in cerebrospinal fluid: A biochemical marker for neuronal degeneration in dementia disorders?. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 8, 183-191.	1.2	43
1383	Formulas for the quantitation of intrathecal IgG production. Journal of the Neurological Sciences, 1994, 121, 90-96.	0.3	37
1384	Ubiquitin in Cerebrospinal Fluid in Alzheimer's Disease and Vascular Dementia. International Psychogeriatrics, 1994, 6, 13-22.	0.6	37
1385	Neuropeptidergic and Monoaminergic Function in Suicide Victims. Neuropsychopharmacology, 1994, 11, 265-265.	2.8	0
1386	Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1993, 5, 5-15.	1.2	38

#	Article	IF	CITATIONS
1387	Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18–88 years of age. European Neuropsychopharmacology, 1993, 3, 55-61.	0.3	59
1388	Protein Analysis in Cerebrospinal Fluid. European Neurology, 1993, 33, 129-133.	0.6	162
1389	Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiology of Aging, 1992, 13, 107-113.	1.5	52
1390	Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. Aging: Clinical and Experimental Research, 1992, 4, 301-6.	0.3	14
1391	Subcortical symptoms predominate in vascular dementia. International Journal of Geriatric Psychiatry, 1991, 6, 137-145.	1.3	39
1392	Presence of parieto-temporal symptomatology distinguishes early and late onset Alzheimer's disease. International Journal of Geriatric Psychiatry, 1991, 6, 147-154.	1.3	47
1393	Gangliosides in Cerebrospinal Fluid in 'Probable Alzheimer's Disease'. Archives of Neurology, 1991, 48, 1032-1035.	4.9	75
1394	Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurologica Scandinavica, 1990, 81, 323-326.	1.0	148
1395	Confusional symptomatology distinguishes early- and late-onset Alzheimer's disease. Aging: Clinical and Experimental Research, 1990, 2, 395-401.	0.3	4
1396	Intra-blood-brain-barrier synthesis of immunoglobulins in patients with dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders, 1990, 4, 79-86.	0.6	11
1397	CSF-Phospho-tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies., 0,, 285-291.		13
1398	CSF Markers for Early Alzheimer's Disease. , 0, , 275-283.		0
1399	Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. , 0, .		1